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ABSTRACT 
 
Delivery of Proteins in Live Cells with Viral Peptides: Principle and Mechanisms.   
 (May 2011) 
Ya-Jung Lee, B.A., National Chung Hsing University;  
M.S., National Yang-Ming University 
Chair of Advisory Committee: Dr. Jean-Philippe Pellois 
 
   Cell-penetrating peptides (CPPs) mediate the delivery of macromolecules across the 
plasma membrane of live cells. These peptides are therefore important due to the 
potential of making the delivery of protein probes or therapeutics a routine procedure. 
However, CPP-mediated delivery is currently an inefficient process. CPP-protein 
conjugates are internalized into cells by endocytosis and the macromolecules remain 
trapped inside endosomes instead of reaching the target cellular localization. To solve 
this problem, we report a delivery methodology which relies on the use of a chimera of 
the TAT (transcription transactivator) and of the Influenza haemagglutinin protein, HA2. 
TAT is a prototypical CPP that can promote macropinocytosis in live cells and HA2 is a 
pH-sensitive peptide that destabilizes lipid membranes upon acidification. I demonstrate 
that HA2-TAT can deliver a variety of macromolecular cargos into live mammalian cells 
by a simple co-incubation protocol. A model is described where TAT causes the 
endocytic uptake of cargos present in the media and that HA2 disrupts the endosomal 
membrane upon endosomal acidification. In addition, using red blood cells as a model 
 iv
system, HA2-TAT binds to membranes in a pH-dependent manner and causes the 
formation of pores through which macromolecules can diffuse. Additionally, the 
pro-apoptotic domain (PAD) peptide is also successfully delivered by HA2-TAT and 
shows significant apoptosis in cells through macropinocytosis.  
   HA2-TAT is a peptide-based delivery agent that combines the pH-sensitive HA2 
fusion peptide from influenza and the cell-penetrating peptide TAT from HIV. This 
chimeric peptide is engineered to induce the cellular uptake of macromolecules into 
endosomes via the TAT moiety and to respond to the acidifying lumen of endosomes to 
cause membrane leakage and release of macromolecules into cells via the HA2 moiety. 
Using fluorescence microscopy with live cells and hemolysis assays with red blood cells, 
the fundamental understanding of HA2-TAT-mediated protein delivery are revealed.  
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NOMENCLATURE 
Antp antennapedia homeodomain 
Bcl-XL B-cell lymphoma-extra large 
BSA bovine serum albumin 
CBD chitin binding domain 
Cdc42 Cell division control protein 42 homolog 
CPP cell penetrating peptides 
DIEA N,N-Diisopropylethylamine 
DMEM dulbecco's modified eagle medium 
DMF dimethylformamide 
(E)GFP (enhanced) green fluorescent protein 
FBS fetal bovine serum 
FGF-2 Fibroblast growth factor 
FITC fluorescein isothiocyanate 
FRET Förster resonance energy transfer 
GTPase guanosine triphosphate hydrolase 
GUV giant unilammilar vesicles 
HA haemagglutinin protein 
HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
 hexafluorophosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC high-performance liquid chromatography 
 viii
HSPG heparin sulfate proteoglycan 
IMPACT Intein Mediated Purification with an Affinity Chitin-binding Tag 
IPTG isopropyl -D-1-thiogalactopyranoside 
kDa kilo dalton 
LUV large unilammilar vesicles 
MALDI matrix-assisted laser desorption/ionization 
MAP model amphipathic peptide 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MVB multivesicular bodies 
NMR nuclear magnetic resonance 
p53 protein 53 
PAD pro-apoptotic domain 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
PTD protein transduction domains 
RBC red blood cell 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPPS solid phase peptide synthesis 
SUMO small ubiquitin-like modifier 
TAT Transcription activaTor 
TCEP tris(2-carboxyethyl)phosphine 
TFA Trifluoroacetic acid 
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TMR tetramethylrhodamine 
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1. INTRODUCTION 
1.1 History of protein delivery
The plasma membrane separates extracellular macromolecules from materials 
within the cell.  Because the plasma membrane is hydrophobic, most protein molecules, 
which are hydrophilic, cannot pass this barrier (1-4). Nevertheless, manipulations such 
as microinjection, electroporation and bead loading have been used to introduce proteins 
into live cells (5,6). However, these methods still need improvement in practicality, 
cytotoxicity and efficiency (7-10). In another approach, a class of short peptides has 
been shown to facilitate protein delivery (7-10). 
In 1988, Loewenstein and Pabo’s groups independently discovered that a 
transcription transactivator, TAT from HIV-1 virus, was taken up by tissue-cultured cells 
after protein incubation in the culture medium. After TAT translocated into cells, it 
rapidly executed its biological function to transactivate viral genes (11,12). Since 
proteins and large molecules are poorly internalized by cells, Green and Loewenstein 
suggested that TAT may bind to an unknown cellular receptor and subsequently undergo 
translocation into cells (12). However, Frankel and Pabo demonstrated that 
internalization of TAT into cells is independent of any receptors (13). These findings 
established that protein transduction into cells by simple incubation was possible. This 
also raised the possibility that proteins could be delivered into cells without any 
complicated manipulations. In 1998 Lebleu and coworkers showed that the minimal 
region corresponding to 47YGRKKRRQRR57 is required for TAT transduction (14). This  
____________ 
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indicates that only a small portion within a particular protein can promote the    
delivery of the entire protein.  
 Following the discovery of the TAT peptide, other peptides that transport proteins 
into cells have been found (14). Such peptides are called protein transduction domains 
(PTDs) or cell-penetrating peptides (CPPs) (15). Most of these peptides are less than 30 
amino acids long and derived from proteins or chemically synthesized (16-18). Like 
TAT, many CPPs are rich in positively charged residues or are amphipathic (17,19) 
(TABLE 1-1). Because of the possible therapeutic value of the ability to deliver proteins 
across the cell membrane, there is interest in 1) the identification of novel CPPs, 2) the 
biological applications of CPP-cargo conjugates in vitro/vivo and 3) the molecular 
mechanism of CPP-cargo delivery (17).  
1.2 Development of CPPs as general delivery tools 
CPPs have been shown to deliver different therapeutic proteins and peptides 
(7,20,21). The tumor supressor p53 (protein 53) was delivered by Antp (antennapedia 
homeodomain) and this restored p53 functions in cancer cells. Bcl-XL (B-cell 
lymphoma-extra large) delivered by TAT can regulate apoptosis and induce 
cytoprotection with retinal ganglion cells (9,19). An important breakthrough in the CPP 
field also came from the first proof-of-concept of their in vivo application.  Dowdy’s 
group showed that 120-kDa (kilo dalton) beta-galactosidase protein could be delivered 
by TAT peptide into many different organ tissues and even cross the blood-brain barrier 
the context of protein therapy (15). In addition to delivering proteins, CPPs also carrying  
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nanoparticles and microbeads (2,17,22). In addition, CPPs can deliver cargos into a 
variety of cell types as well (1,23). These findings suggest that neither the cargo types 
nor the target cells are restricted in CPP-mediated cargos delivery i (22,24). CPPs appear 
as general delivery vectors with promising activity.     
 
1.2.1 Potential problem of CPP-mediated protein delivery 
Although CPPs can carry different protein molecules into live cells, limited delivery 
efficiency is still the main bottleneck in this field (17,18,22,25). Only a fraction of 
incubated proteins can be delivered to the intracellular localization by CPPs. Delivery 
efficiency is determined by the biological activity of the delivered cargo. This readout 
confirms that the cargo was not only delivered, but that it also remained in a functional 
state. The increase in a given biological assay will be considered as a successful CPP-
mediated cargo delivery. However, the percentage of cells containing CPP-delivered 
proteins is still low even though protein delivery is achieved (26,27). Although many 
studies aim to explore the delivery efficiency of CPPs, the result still remains unclear 
(26,27). To be able to utilize CPPs as general delivery vector, the low efficiency problem 
of CPPs needs to be improved. Understanding the cellular mechanism of CPP-mediated 
protein delivery definitely is necessary in order to enhance the delivery efficiency of 
CPPs.  
 
1.3 Proposed mechanism of protein delivery by CPP  
Different entry routes of CPP-mediated protein delivery have been reported (1,16, 23,
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28). Even though some discrepancies remain, a current model of CPPs uptake involves 
the three following steps: i) binding on the cell surface, followed by ii) stimulation of 
macropinocytotic uptake into macropinosomal vesicles and finally iii) escape from 
endosomes into the cytoplasm (10,17). This study will be focused on the most well-
studied CPP, TAT. 
 
1.3.1 Cell surface binding 
Once TAT is present in the cellular media, binding between TAT and plasma 
membrane can occur. Since TAT-mediated protein uptake is cell-type independent, it is 
hypothesized that there is no specific receptor mediating the association between TAT 
and membrane (13,29-31). In addition, it is proved that positively charged arginine 
residues in TAT sequence (TAT containing 6 arginines out of 10 residues) are essential 
to facilitate CPP transduction (31-33). The guanidine group of arginine can form 
bidentate hydrogen bonds with sulfate, phosphate or carboxylate anions (33-36). Such 
interactions raise the possibility that TAT may bind to many cell surface molecules (34).
Based on findings from studies of TAT-mediated protein transduction, a model 
regarding the initiation of TAT-mediated protein delivery has been proposed. The 
positive arginine residues of TAT exhibit high affinity with heparin sulfate proteoglycan 
(HSPG), the anionic sulfated proteoglycans on extracellular matrix of plasma membrane 
through electrostatic interaction. This interaction facilitates TAT-mediated protein 
delivery through endocytosis (7,17). It is also known that most of HSPG on the cell 
surface are linked to two core protein families, the transmembrane syndecans and the 
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membrane lipid-anchored glypicans (37-39). Syndecan has been shown to be responsible 
for uptake of FGF-2 (Fibroblast growth factor) by macropinocytosis. This suggests that 
syndecan might serve as a binding reservoir for TAT. This binding event might also 
initiate macropinocytosis (40).  
 
 1.3.2 Endocytic uptake and endosomal maturation 
Different endocytic routes have been implicated as pathways for internalization of 
different CPPs with various types of cargos. These routes include caveolin, clathrin-
dependent endocytosis and the major route, macropinocytosis (16,23,28). This is also 
supported by the discovery that TAT fusion cargos can induce the uptake of neutral 
dextran, a marker of fluid phase endocytosis (36,41). Compared to other endocytosis 
pathways, macropinocytosis is not well characterized (42,43). Macropinocytosis occurs 
at regions of actin-induced membrane ruffling and protrusions (43,44). These 
protrusions create vesicles either by the fusion of two protrusions or of a protrusion and 
the membrane near the origin of this protrusion (43,44). Macropinocytosis is a form of 
fluid phase endocytosis performed by all cells, wherein the vesicles take up the 
surrounding medium (17,45,46). The exact structural changes and proteins involved in 
macropinocytosis, still need to be elucidated. After macropinocytosis is induced, TAT-
conjugated protein internalize into endocytic vesicles (9,17,46,47). These compartments 
can then undergo multiple steps of maturation. Partition may occur into various 
endocytic organelles, including sorting endosomes (also called early endosomes), 
recycling endosomes, multivesicular bodies (MVB), late endosomes and fuse with 
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lysosomes (25,28,45,48). If TAT-conjugated protein fails to be released from endosomal 
vesicles before endosome-lysosome fusion, they will be subjected to lysosomal 
degradation (10,49,50).   
 
1.3.3 Endosomal escape: The limiting step 
Both the mechanism and the efficiency of the endocytosis of TAT-mediated protein 
delivery have been addressed in many studies.  After endocytosis, TAT-conjugated 
protein still needs to be released from the endosome to reach its target cellular locale and 
begin to function biologically (1). However, it is reported that a large fraction of TAT-
conjugated cargos are trapped in endosomes and are not released into cytosolic space 
(26,27,41). Therefore, endosomal escape seems to be the limiting step during TAT-
mediated protein delivery. This is a key factor that leads to low protein delivery 
efficiency (17,26,27,41). This critical step, endosomal escape, remains obscure, as do 
later processes in the endocytic pathway (9,17). Some research groups have started 
making efforts to explore this particular step (26,27,41). 
 
1.3.4 Endosomal escape model  
Despite the poor understanding of endosomal escape, TAT is able to disrupt the 
endosomal membrane without interfering with the plasma membrane and causing 
cytotoxicity (14,32). As endosomal vesicles are newly formed from the plasma 
membrane during endosomal maturation, the enrichments in specific membrane lipids 
and membrane-associated small Rab GTPases (guanosine triphosphate hydrolase) are 
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altered in all classifications of vesicles (39,51,52). Moreover, the pH in endocytic 
vesicles from early to late endosomes or lysosomes is found to decline from pH 7.2 to 
4.5 (48,53). 
The changes in membrane protein and lipid compositions and decreasing in pH 
within endosomes are suggested leading to TAT-induced endosomal membrane escape 
(27,38,54). However, the effects of these factors in TAT-related endosomal membrane 
disruption are not fully defined (27). Furthermore, even though TAT is reported as the 
most efficient CPP, endosomal entrapment of TAT still results in poor delivery 
efficiency (41,55). Therefore, in this study, I will explore this critical step, endosomal 
escape, and attempt to design a more active CPP. Our proposed TAT-mediated protein 
delivery mechanism is illustrated in Fig 1-1. (TAT associates with HSPG on the cell 
surface to induce endocytosis. Next, TAT-mediated proteins are internalized into 
endosomes. The later processes in the endocytic pathways remain unclear. But somehow 
TAT-mediated proteins need to be released from endosomes and reach the target cellular 
localizations in order to execute their biological functions). 
 
1.4 The possible solution for low CPP delivery efficiency:  HA2-TAT,  enhances  the
      limiting step, endosomal escape 
Some virus particles infect host cells through an endocytic pathway (56-58). After 
endocytosis, the viral membrane and endosomal membrane undergo destabilizing then 
fuse with each other during endosomal acidification (58,59). This fusion event results in 
releasing viral nucleic acids to the nucleus in host cells for viral propagation (56,60,61). 
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The Influenza virus belongs to the class of virus that infects through endocytosis. 
(56,60,61). Haemagglutinin (HA) is the main glycoprotein of the influenza (H3N2) virus 
that mediates viral fusion with endosomes (5,56,62) . It is a homotrimer of 200 kDa. 
Each monomer is composed of two disulfide-linked subunits, HA1 and HA2 (5,56,62). 
HA1 is responsible for initiating the binding of influenza virus to sialic acid-containing 
receptors on the host membrane. HA2 regulates the fusion event between the viral 
membrane and the endosomal membrane (61,62). Since endosomal escape of CPP-
mediated protein may be correlated with decreasing in pH inside of endosomal lumens, 
HA2 has been utilized to enhance endosomal escape (21,41,60). 
The N-terminal segment of HA2 subunit, composed of twenty nonpolar amino acids 
(1GLFGAIAGFIENGWEGMIDG20), is required for endosomal fusion (56,63,64). In 
addition, the membrane fusion activity is profoundly decreased by deletion or mutation 
of its N-terminal Gly1 (64,65). Since HA2 protein induces membrane fusion during 
endosomal acidification, the 20 residue HA2 peptide, is considered as a pH-sensitive 
membrane disruption peptide (60,63). 
1.4.1 The  pH-dependent   conformational   change  of   HA2   peptide   leads  to  its
         destabilizing activity  
Based on circular dichroism studies, the helicity of HA2 increases upon a decrease 
in pH (62,66,67). This conformational change leads to the association of the peptide with 
the lipid membrane. This interaction then causes membrane destabilization (62,66,67). 
Hence, HA2 peptide can disrupt the endosomal  membrane  during endosomal acidifying 
10 
 
1 GLFGAIAGFIENGWEGLIDG 20 
Figure 1-1 The helical structure model of HA2 peptide. 
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(usually pH 5-7). As a result, lysis of endosomal membrane might be achieved without 
causing lysis of the plasma membrane or other membraneous organelles. Similarly, HA2 
peptide can also enhance endosomal escape during CPP-mediated protein delivery in 
acid environment. Indeed, HA2 peptide has been fused to the N-terminus of the tumor 
suppressor p53 modified with the CPP R11. The formed HA2-p53-R11 construct was 
shown to reduce the proliferation of cancer cells more efficiently than p53-R11 alone 
(60). In addition, the D-form dTat-HA2 peptide markedly enhanced the release of Tat-
Cre from macropinosomes and displayed the cre recombinase activity (then induced 
EGFP protein expression) in live cells compared to Tat-Cre delivery only. (41). 
 
1.4.2 Protonation  of  negatively charged residues of HA2 peptide contributes to the   
         lipid membrane disruption in acidic environment
HA2 peptide is an amphipathic sequence. In the -helical wheel model of this 
peptide, one face of the proposed helix is rich in hydrophilic residues while the opposite 
face is rich in hydrophobic residues (66,67). When HA2 peptide is adjacent to the 
surface of a lipid bilayer, the hydrophobic side of the helix shows higher affinity for the 
lipid membrane, whereas the hydrophilic side is exposed to the aqueous environment 
(66,67) (Fig 1-2). Once pH decreases, carboxyl groups on the Glu11, Glu15, and Asp19 
side chains will be protonated. The peptide is more hydrophobic due to neutralization of 
those charged residues. Neutralization can augment the affinity of HA2 peptide for the 
lipid bilayer (62,66,68). Furthermore, the protonation of acidic residues induces a 
conformational  change  of  HA2  peptide  to  a  higher  helical  content  of its C-terminal 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 A cartoon representation of the secondary conformational change of HA2 
peptide in the presence of lipid membrane at neutral pH (pH 7) and pH5. The arrows 
indicate the positions of Glu11, Glu15, Asp 19. Hydrophilic residues are highlighted in 
red and hydrophobic residues are highlighted in black. 
 
 
 
 
 
13 
 
peptide with a hinge formation between Gly12-Gly13 (56,62,69). The neutralized C-
terminal -helical peptide facilitates the insertion into lipid bilayers (Fig 1-2).This results 
in membrane disruption at acidic environments (56,65,68). (In another words, the 
electrostatic repulsion among the negatively charged residues, prevents the stable C-
terminal -helix formation at neutral pH (63,65,70). This is believed to be the key factor 
that contributes to pH-dependent, HA2-mediated membrane disruption).  
 
1.4.3 HA2E5, higher membrane disruption activity 
HA2 peptide has been shown to enhance endosomal release for protein delivery and 
nucleic acid transfection (41,60,70,71). However, this peptide is extremely aggregative, 
and poorly dissolvable in aqueous media, and therefore was difficult to characterize 
spectroscopically (62,69). Its solubility behavior limits its usefulness (62,69), so many 
studies have been focused on enhancing membrane disruption activity and the solubility 
of HA2 peptide. Due to the proposed mechanism, additional glutamic acid residues have 
been introduced in HA2 peptide to enhance the pH-dependent membrane disruption 
activity (and solubility) (63). The hydrophilic side chains of Gly4 and Gly8 along with 
Glu11, Glu15 and Asp19 on the -helix structure of HA2 peptide are all located on the 
exterior of the lipid bilayer (Fig 1-3) (68). Studies of the HA2 peptide mutant, HA2E5, 
which includes G4E, G8E, and D19E, (GLFEAIAEFIENGWEGMIEG, five glutamic 
acids) showed  that  these mutated residues play a pivotal role not only in enhancing pH-
dependent membrane disruption activity, but also peptide solubility (57,66). In liposomal 
assays, HA2E5 exhibited a higher extent of liposomal fusion and leakage than wild type   
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Figure 1-3 A cartoon representation of the possible structure of the E5 analog at 
fusogenic pH, with a helix-hinge-helix structural motif in the interface of water and lipid 
membrane.  
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HA2 peptide at pH5, but not at pH7 (66,69). The NMR (nuclear magnetic resonance)
study resolved that the C-terminal helix of HA2E5 sequence is inserted deeper into the 
lipid bilayer. The deeper insertion and the hinge formation between Gly12-Gly13 both 
contribute to destabilize the membrane (65). These findings provide insights into the 
molecular mechanism of increased membrane disruption by HA2E5.
 
1.5 The goal of my study 
Although previous studies demonstrated that HA2 peptide appeared to enhance 
endosomal release for CPP-mediated protein delivery (2,41,60), little is known about 
how HA2 peptide mediates this particular step. This is partly because it is difficult to 
investigate endosomal escape in a complex, cellular environment where many other 
processes take place. In addition, simpler but more controllable lipid bilayer models such 
as liposomes often fail to reproduce the peptide activities observed in cells (4). To study 
the effects of HA2 on endosomal escape comprehensively, I will utilize in vitro systems. 
The HA2 peptide and HA2 peptide mutant, HA2E5, fused to TAT will be used as the 
main chimeric CPPs in my study. HA2-TAT possesses both the delivery properties of 
TAT and the endosomal escape activity from HA2. My work will focus on investigating 
theendosomalytic activity of HA2-based peptides in cellulo and in vitro. The The 
knowledge acquired in this study will lay the foundation for the design of more efficient 
CPPs. 
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2. HA2-TAT PEPTIDE TAGS FOR THE DELIVERY OF PROTEINS 
2.1 Introduction 
In this section, I highlight the usefulness of HA2 peptide and the HA2 analog, E5 
(HA2E5), as endosomolytic reagents that can improve the delivery of macromolecules 
into live cells. HA2 and E5 fused with TAT-mCherry protein will be the constructs to 
test the hypothesis that fusion of these peptide tags increases the delivery of 
macromolecules into the cytosolic space of live cells. The hydrophobicity of HA2 
peptide is often problematic, and it is therefore unclear how this peptide might affect the 
biophysical and cellular properties of a protein fused to it. To answer these questions, the 
effects of additional HA2 tags on TAT-mCherry will also be also investigated. 
 
2.2 Results 
Two different HA2 sequences were fused to the N-terminus of the protein TAT-
mCherry. These sequences consist of the wild-type HA2 peptide and of E5. HA2 and E5 
typically are N-terminal because the peptides typically need to have a free N-terminal 
glycine to display a lytic activity and TAT is present to promote endocytosis of mCherry 
into live cells. mCherry was chosen as the model cargo because this protein is 
monomeric, soluble, non-cytotoxic and without a cellular activity. The rationale is 
therefore that the effects of HA2 and E5 would be easy to identify since the protein 
cargo itself should not interfere with the assays. mCherry is also fluorescent and the 
trafficking of this protein inside live cells can be monitored by fluorescence microscopy. 
17 
 
Finally, mCherry remains folded at pH as low as 4.0. The lytic activity of HA2 or E5 at 
acidic pH can therefore be assayed without causing denaturation and precipitation of the 
protein.  
To study the property of the HA2 and E5 peptide tags, mCherry, TAT-mCherry, 
HA2-TAT-mCherry and E5-TAT-mCherry were cloned, over-expressed and purified 
using the IMPACT (Intein mediated purification with an affinity chitin-binding tag) 
system (Table 2-1). To note, the extended WYG residues on the C-terminal of HA2 have 
been shown to enhance the deliver efficiency (70). HA2-TAT-mCherry, and E5-TAT-
mCherry were cloned with an N-terminal SUMO (small ubiquitin-like modifier) tag and 
the SUMO protease was used to generate the desired N-terminal sequences (confirmed 
by Edman sequencing).  
 
2.2.1 Protein solubility and aggregation propensity analysis 
HA2 peptides are known to have a high propensity to aggregate and precipitate in 
aqueous media (62). To investigate whether HA2 and E5 would affect the behavior of 
TAT-mCherry in water, the solubility of each of the protein constructs was first assessed 
using a HPLC (high-performance liquid chromatography) -based assay. HA2-TAT-
mCherry and E5-TAT-mCherry were incubated at 37°C in PBS (phosphate buffer saline) 
with the pH adjusted to 7.0 or 4.5. These pH values correspond approximately to the pH 
extremes the proteins might encounter while transiting within endocytic organelles. 
Immediately after mixing the reagents or after an overnight incubation, the samples were 
centrifuged  to  pellet  insoluble aggregates. The  amount  of soluble protein remaining in  
18 
 
Table 2-1 Sequences of the HA2-TAT peptides investigated  
Name Amino Acid Sequence  Mw (Da) 
HIV TAT (48-57) GRKKR RQRRR  
Influenza HA2 (1-23) GLFGA IAGFI ENGWE GMIDG WYG  
TAT-mCherrya GR KKRRQ RRR 29585 
HA2-TAT-mCherrya,b GLFGA IAGFI ENGWE GMIDG WYGGR KKRRQ RRR 31896 
E5-TAT-mCherrya,b GLFEA IAEFI ENGWE GLIEG WYGGR KKRRQ RRR 32036 
a the sequence represented is at the N-terminus of mCherry 
b the underlined sequence represents the sequence analyzed by Edman sequencing. 
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of mCherry, TAT-Cherry, and E5-TAT-mCherry was not affected by incubation time or 
pH. In contrast, HA2-TAT-mCherry showed an approximately 40% decrease in soluble 
content when exposed to pH 4.5 after an overnight incubation. Importantly, the protein 
mCherry does not unfold under these conditions and precipitation can therefore be 
attributed to the HA2-TAT tag. 
In addition to being poorly soluble, HA2 peptides have been shown to self-associate 
in solution (57). The oligomerization propensity of the protein constructs was 
investigated by Size Exclusion Chromatography (SEC). mCherry and TAT-Cherry 
eluted as monomers with the expected molecular weight of  approximately 29 kDa. In 
contrast, HA2-TAT-mCherry eluted in the column’s dead volume, indicating that 
soluble aggregates with molecular weights superior to 200 kDa were present in the 
sample. Only a small fraction of the sample (<5% based on the integrated peak area) 
eluted as a monomer. In the case of E5-TAT-mCherry, two elution peaks indicating the 
formation of possible trimers and dimers were present (Fig. 2-1A). Sedimentation 
velocity analytical ultracentrifugation was performed on E5-TAT-mCherry to confirm 
these results. However, the sedimentation coefficient obtained from this sample was 2.6 
± 0.1, a value similar to that obtained for TAT-mCherry (2.5 ± 0.1) and corresponding to 
a molecular weight of approximately 27.5 ± 0.5 kDa. The protein therefore appears to be 
monomeric in this experiment. A possible explanation for the discrepancy between the 
size exclusion and sedimentation results is that E5-TAT-mCherry might form weakly 
bound oligomers that remain associated during SEC but not during analytical 
ultracentrifugation. Finally, the difference in aggregation propensity between HA2-TAT-  
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Figure 2-1 Biochemical analysis of E5-TAT-mCherry. A) Size exclusion 
chromatography of TAT-mCherry, HA2-TAT-mCherry, and E5-TAT-mCherry. The 
void volume and elution volume of standards with known molecular weights are 
indicated with black arrows. B) Electron microscopy images of aggregated HA2-TAT-
mCherry and HA2-TAT. No aggregates were detected when E5-TAT-mCherry or E5-
TAT were analyzed under similar conditions. 
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mCherry and E5-TAT-mCherry was further revealed by electron microscopy. Consistent 
with the SEC analysis, no large aggregate could be observed for E5-TAT-mCherry. In 
contrast, fibrils with a diameter of 260-290 Å were readily observed with HA2-TAT-
mCherry, (HA2-TAT alone showed fibrils of 86Å in diameter) (Fig. 2-1B). Overall, 
these results suggest that HA2 has a strong propensity to aggregate and that its addition 
to the N-terminus of a protein causes the formation of large yet soluble protein 
aggregates. In contrast, aggregation is much reduced when the protein is labeled with E5.    
 
2.2.2 Cytotoxicity of the protein constructs 
The cytotoxicity of mCherry, TAT-mCherry, HA2-TAT-mCherry and E5-TAT-
mCherry toward HeLa cells was assessed using the MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. As expected, the innocuous mCherry did not 
display significant cytotoxicity in the concentration range tested (2.5 -10 M). Addition 
of TAT caused a modest increase in the cytotoxicity of the protein. In contrast, HA2-
TAT-mCherry was significantly more cytotoxic, indicating that the addition of HA2 
affects the interaction between the protein and cells. Interestingly, HA2-TAT-mCherry 
was less toxic than HA2-TAT alone at 5 or 10 M, indicating that the protein moiety 
reduces the toxicity of the peptide. Finally, E5-TAT-mCherry had a cytotoxicity which 
was comparable to that of TAT-mCherry. The mutations present in E5 as compared to 
HA2 therefore appear to be sufficient to reduce the cytotoxicity of the peptide (Fig. 2-2).  
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Figure 2-2 Viability of HeLa cells incubated with TAT-mCherry, HA2-TAT-mCherry, 
and E5-TAT-mCherry. The cytotoxicity of the delivery peptides alone was also tested 
for comparison. Cells were treated with the molecules at the concentrations displayed for 
1 hour, washed, and incubated in fresh media for an additional 3 hours. Viability was 
then measured using the MTT assay. 
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2.2.3 Hemolytic activity of HA2-TAT-mCherry and E5-TAT-mCherry as a function
          of pH
The hemolysis activities of HA2-TAT-mCherry and E5-TAT-mCherry were 
characterized by an in vitro erythrocyte lysis assay (Fig. 2-3). HA2-TAT-mCherry and 
E5-TAT-mCherry were incubated with human RBCs (red blood cells) in PBS with a pH 
adjusted to different values. The release of hemoglobin from lysed red blood cells was 
then measured spectrophotometrically at 450 nm (at the concentrations used, the 
absorbance of mCherry does not contribute to the signal). The control proteins mCherry 
and TAT-mCherry did not cause any hemolysis at any of the conditions tested (up to 20 
M, pH 4.0-7.5). Unexpectedly, HA2-TAT-mCherry did not cause lysis either (up to 20 
M, pH 4.0-7.5). In contrast, E5-TAT-mCherry caused hemolysis at pH values below 
6.0 (Fig. 2-3A). However, the hemolytic activity of E5-TAT-mCherry was quite reduced 
in comparison to E5-TAT. The pK50, or pH at which 50% hemolysis is achieved, was 
reported to be 6.7 for E5-TAT but appears to be approximately 5.7 for E5-TAT-mCherry. 
E5-TAT-mCherry also needs to be approximately 10-fold more concentrated than E5-
TAT to achieve a similar hemolytic yield (Fig. 2-3B). 
  
2.2.4 Characterization of the cellular distribution of HA2-TAT-mCherry and E5- 
          TAT-mCherry  
The transduction activities of HA2-TAT-mCherry and E5-TAT-mCherry were 
tested by incubating the proteins with HeLa cells. The proteins mCherry and TAT-
mCherry  were  used  for  comparison.  A  70  kDa  dextran-fluorescein  was  also  added 
24 
 
 
 
 
 
 
 
 
 
 
Figure 2-3 A) Hemolytic activities of TAT-mCherry and E5-TAT-mCherry as a 
function of pH. Hemolysis is reported as a percentage of the maximal release of 
hemoglobin obtained by treatment of the red blood cells with the detergent Triton X. B) 
Hemolytic activities of E5-TAT and E5-TAT-mCherry at pH 7.0, 5.0 and 4.0 as a 
function of peptide or protein concentration for 1.25% RBC suspensions.  
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as a marker of pinocytosis. After 1 hour incubation with HeLa cells, TAT-mCherry and 
dextran-fluorescein colocalized and displayed a punctate distribution consistent with 
these molecules being localized within endocytic organelles. Similar observations were 
made with HA2-TAT-mCherry and E5-TAT-mCherry. However, in contrast to TAT-
mCherry, both HA2-TAT-mCherry and E5-TAT-mCherry were associated with the 
plasma membrane of cells. The proteins initially appeared homogeneously distributed on 
the cell surface. However, large fluorescent clusters seemed to form within 20 min of 
examination, suggesting that the proteins might aggregate on the cell surface over time. 
The protein residing at the plasma membrane could be washed by treatment with heparin, 
a negatively charged and soluble glycosaminoglycan known to inhibit the binding of 
TAT to membrane bound heparan sulfate proteoglycans (72-74). Addition of heparin to 
HA2-TAT-mCherry and E5-TAT-mCherry during incubation with cells also prevented 
the binding of the proteins to the membrane of cells and endocytic uptake (Fig. 2-4). 
These results indicate that the binding of HA2-TAT-mCherry and E5-TAT-mCherry to 
the plasma membrane is in part mediated by TAT. Yet, since the membrane staining of 
HA2-TAT-mCherry and E5-TAT-mCherry but not TAT-mCherry showed large 
fluorescent clusters, it appears that both HA2 and E5 increase the retention of the protein 
aggregate at the plasma membrane.
 
2.2.5 Characterization of the endosomolytic and cytosolic release activities of HA2-
         TAT-mCherry and E5-TAT-mCherry  
        HA2-TAT-mCherry and   E5-TAT-mCherry  co-localized  with  70   kDa  dextran- 
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Figure 2-4 Microscopy images of HeLa cells incubated with TAT-mCherry or E5-TAT-
mCherry (5 M, 1 hour incubation). Both TAT-mCherry and E5-TAT-mCherry have a 
punctate distribution that is consistent with accumulation of these proteins within 
endocytic organelles. However, E5-TAT-mCherry also remains associated with the 
plasma membrane even after extensive washing with fresh media (as shown in confocal 
and 3D projection images). Addition of heparin to the washing media reduces the 
amount of protein bound to the plasma membrane and the protein accumulated within 
endocytic organelles appears more clearly. Addition of heparin during incubation 
suppresses both plasma membrane binding and accumulation within endocytic 
organelles. 
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fluorescein within endocytic organelles but the proteins did not appear to diffuse into the 
cytosolic space of the cells examined. However, in approximately 5% of the cells 
incubated with E5-TAT-mCherry, the fluorescent dextran had a cytosolic distribution as 
well as a punctate distribution (Figs. 2-5 and 2-6, the punctate distribution of the 
fluorescent signal observed in the cytosol is less than that of the dextran left inside 
endocytic organelles). These cells were not stained by SYTOX Blue, indicating that the 
permeability of the plasma membrane of these cells was not compromised post-
incubation. The cytosolic distribution of dextran was not observed when E5-TAT-
mCherry was not added to the incubation media or when TAT-mCherry was used. These 
results therefore indicate that the E5 moiety in E5-TAT-mCherry might be involved in 
mediating the transport of the dextran into the cell cytosol. However, the mechanism by 
which E5-TAT-mCherry might mediate the endosomal release of dextran-fluorescein 
could not be investigated precisely because of the low efficiency of this process. 
Nonetheless, the observation that E5-TAT-mCherry was not distributed in the cytosol of 
cells that showed endosomal release of dextran-fluorescein is intriguing. Instead, the 
distribution of E5-TAT-mCherry remained punctate. These results therefore suggest that 
the protein might still be associated with endosomes (co-localization of E5-TAT-
mCherry and dextran-fluorescein in these fluorescent spots confirm that the punctate 
distribution corresponds to endocytic organelles loaded with both species rather than 
protein aggregates that might have form protein aggregates that might have formed once 
the protein escapes into the cytosolic space, Fig. 2-7). The gyration radius of 70 kDa 
dextran-fluorescein  is  approximately 18  nm  while  the radius  of  the 32 kDa E5-TAT- 
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Figure 2-5 Fluorescence microscopy of HeLa cells incubated with E5-TAT-mCherry (5 
M) and 70 kDa Dextran-fluorescein (Dx-Fl). Images were obtained with a 10 X 
objective. The fluorescence signals are represented in inverted monochrome images or in 
an overlay image (mCherry is pseudo-colored red and fluorescein is pseudo-colored 
green). The fluorescence signal of E5-TAT-mCherry associated with cells corresponds 
to a punctate endocytic distribution not discernable at 10 X but discernable at 100 X (see 
Fig. 2-6). The fluorescence signal of Dx-Fl observed is that of molecules delivered into 
the cytosolic space of cells (the fluorescence signal of fluorescein is quenched inside 
acidic endocytic organelles and, at 10 X, this signal is not detectable under the imaging 
conditions used). Only 5% of the cells examined have an observable fluorescein signal. 
This is increased to 60% when the endosomolytic peptide E5-TAT was added to the 
incubation media. Addition of bafilomycin, an inhibitor of endosomal acidification, 
however reduced the release of Dextran-fluorescein into the cytosolic space of cells to 
non-detectable levels (Dextran-fluorescein is still present within endocytic organelles, 
see Fig. 2-6). The distribution of E5-TAT-mCherry remains unchanged in these 
experiments, indicating that the protein is associated with endocytic organelles 
regardless of whether endosomal lysis is achieved or not. The cells represented were not 
stained by SYTOX Blue, indicating that the plasma membrane of these cells is not 
compromised. 
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Figure 2-6 Fluorescence microscopy of HeLa cells incubated with E5-TAT-mCherry, 
TAT-mCherry and mCherry. Images were obtained with a 100 X objective. A 70 kDa 
Dextran-fluorescein (Dx-Fl) was used during incubation to detect the endosomal release 
of endocytosed molecules (as detected by its diffuse cytoplasmic distribution 
accompanied by nuclear exclusion). In the case of TAT-mCherry and mCherry, 
endosomal release was induced by addition of the endosomolytic peptide E5-TAT in the 
incubation media. For TAT-mCherry and mCherry cells with a cytosolic distribution of 
Dx-Fl also show a protein distribution in the cytosolic and nuclear spaces. However, in 
the case of E5-TAT-mCherry, cells containing a cytosolic distribution of Dx-Fl do not 
show a cytosolic distribution of the protein but instead a punctate distribution. In all 
cases, the cytosolic distribution of Dx-Fl and proteins was abolished by addition of 
bafilomycin during incubation and imaging. The cells represented were not stained by 
SYTOX Blue, indicating that the plasma membrane of these cells is not compromised. 
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Figure 2-7 Fluorescence microscopy of HeLa cells incubated with E5-TAT-mCherry. 
Images were obtained with a 100 X objective. A 10 kDa Dextran-fluorescein (Dx-Fl) 
was used during incubation to detect the endosomal release of endocytosed molecules 
(as detected by its diffuse cytoplasmic distribution). Dx-Fl showed a protein distribution 
in the cytosolic. However, in the case of E5-TAT-mCherry, cells containing a cytosolic 
distribution of Dx-Fl do not show a cytosolic distribution of the protein but instead a 
punctate distribution. The arrow labeld with 1 indicates Dx-Fl colocalizing with E5-
TAT-mCherry in endosomal vesicles of a cell containing a cytosolic distribution. The 
arrow labeld with 2 indicates Dx-Fl colocalizing with E5-TAT-mCherry in endosomal 
vesicles of a cell containing only punctate distribution of both molecules. 
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mCherry is expected to be less than 10 nm (75). If the larger dextran-fluorescein can 
escape while E5-TAT-mCherry cannot, it is therefore not the size of the protein that 
limits its ability to reach the cytosolic space. 
To address the issue of why E5-TAT-mCherry fails to reach the cytosolic space 
when dextran-fluorescein does, E5-TAT was added to the incubation mixture. The 
principle of this approach is that E5-TAT and macromolecules are endocytosed together 
and that, upon acidification of the lumen of endosomes, E5-TAT causes the release of 
the macromolecules contained inside the endosomes into the cytosolic space of cells 
through formation of pores. The goal was therefore, to determine whether E5-TAT-
mCherry could be released into the cytosol of cells if endosomes were rendered leaky. 
Addition of E5-TAT to the E5-TAT-mCherry and dextran-fluorescein incubation 
mixture greatly increased the population of cells containing dextran-fluorescein 
(approximately 60% of cells, Fig. 2-5). Addition of the vacuolar H+-ATPase inhibitor 
bafilomycin inhibited the endosomal release of dextran-fluorescein. This indicates that 
acidification of the lumen of endosomes is required for the cytosolic delivery of the 
dextran and that E5-TAT mediates this process by causing endosomal release (as 
opposed to plasma membrane permeabilization). Despite this observed increase in the 
number of cells containing dextran-fluorescein in their cytosolic space, addition of E5-
TAT did not increase the delivery of the protein into the cytosol of cells. In contrast, 
addition of E5-TAT led to the cytosolic delivery of mCherry and TAT-mCherry, as 
shown in Fig. 2-6 (accumulation of TAT-mCherry in the nucleus can be observed while 
mCherry has a diffuse distribution throughout the cell, as expected from the 
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microinjection results). Together these results indicate that E5-TAT-mCherry fails to 
reach the cytosolic space because of the E5 moiety. These results also suggest that E5-
TAT-mCherry does not reach the cytosol because it remains associated with endosomes. 
This happens even when endosomal lysis and release of dextran-fluorescein takes place 
and regardless of whether endosomal lysis is mediated by E5-TAT-mCherry itself or by 
the addition of E5-TAT.  
 
2.2.6 Effect of TAT on the intracellular distribution of the model protein mCherry 
To determine the effect that the delivery tags might have on the cellular distribution 
of their mCherry cargos, the proteins TAT-mCherry, HA2-TAT-mCherry, and E5-TAT-
mCherry were microinjected into the cytosol of live HeLa cells. The goal of most 
delivery applications is to deliver a macromolecule into the cytosolic space. The 
distribution of the microinjected macromolecules therefore serves as a model for what 
might be expected after successful delivery with a CPP tag. The proteins were 
microinjected along with a 70 kDa dextran-fluorescein and the distribution of the 
fluorescent molecules were observed by wide-field and confocal fluorescence live cell 
microscopy. The microinjected protein control mCherry was homogenously distributed 
throughout the cell, including the nucleus (Fig. 2-8). This is expected because the 
molecular weight of the protein, 28 kDa, is below the nuclear diffusion threshold (~50 
kDa) (76). The soluble protein can therefore diffuse across the nuclear pore complex. In 
contrast,  the  70  kDa  dextran-fluorescein  is  excluded  from  the  nucleus  and its signal  
confirm that  the  material was microinjected in the cytoplasm as  opposed to the nucleus. 
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Figure 2-8 Fluorescence microscopy of HeLa cells microinjected 70 kDa Dextran-
fluorescein (Dx-Fl) and mCherry, TAT-mCherry, or E5-TAT-mCherry. Nuclear 
exclusion of the 70 kDa Dextran-fluorescein (Dx-Fl) was used to determine that the site 
of microinjection was the cytoplasm. Microinjected mCherry diffuses into the nucleus 
and the protein is distributed homogeneously throughout the cell. TAT-mCherry also 
diffuses into the nucleus and accumulates at nucleoli. In contrast, E5-TAT-mCherry does 
not accumulate in the nucleus and appears retained in the cytoplasm instead. When a 
larger amount of E5-TAT-mCherry is microinjected, the protein appears to accumulate 
at membraneous organelles (insert, accumulation at the nuclear membrane is highlighted 
with a black arrow). 
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TAT-mCherry also diffused throughout the cell. However, in contrast to mCherry, TAT 
led to the accumulation of the protein at the nucleoli (Fig. 2-8). This is a well-known 
effect of TAT and is consistent with reports that have suggested that the sequence 
GRKKR (the TAT sequence is GRKKRRQRRR) acts as a nucleolar localization signal 
(77). Despite containing the TAT moiety, the microinjected HA2-TAT-mCherry and E5-
TAT-mCherry did not accumulate at the nucleoli. Instead, the fluorescence signal of 
these proteins within the nucleus was greatly reduced in comparison to that of the 
cytoplasm. HA2-TAT-mCherry and E5-TAT-mCherry also appeared to have a non-
uniform cytosolic distribution indicative of a possible association with cytoplasmic 
organelles. Direct microinjection of the proteins into the nucleus of cells led to a similar 
cytoplasmic distribution, indicating that the proteins were able to traffic out of the 
nucleus. Together, these observations suggest that HA2-TAT-mCherry and E5-TAT-
mCherry are retained in the cytoplasm because the proteins bind to cytosolic components. 
Overall, covalent attachment of HA2-TAT or E5-TAT to mCherry appears to greatly 
compromise the localization of the protein inside cells.  
 
2.3 Discussion 
      Proteins fused to PTDs, while efficiently internalized by endocytic mechanisms, 
often remain trapped inside endocytic organelles during delivery. Combining the HA2 
peptide with a PTD might provide a solution to this problem since HA2 is expected to 
respond to the acidic environment within endosomes and cause the lysis of the 
endosomal membrane. However, to be useful as a delivery tool, HA2-PTD fusion tags 
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should, in principle, have little effect on the biophysical and intracellular properties of 
their protein cargo. This is based on the notion that a protein delivery tag should not 
perturb the function of its protein cargo and that it should not disrupt the physiology of 
cells during or after delivery. HA2, fused to the N-terminus of the model protein TAT-
mCherry, did not fulfill these requirements. First, HA2 altered the in vitro behavior of 
the protein extensively. While TAT-mCherry is monomeric, HA2-TAT-mCherry formed 
large soluble aggregates. In addition, fusion of HA2 significantly increased the 
cytotoxicity of the protein. These problems were in part resolved by replacing HA2 to its 
analog E5. E5 differs from HA2 by including the G4E, G8E, M17L and D19E mutations. 
Addition of the glutamate residues has been demonstrated to increase the solubility and 
pH dependent lytic activity of HA2 analogs (1, 10, 11). E5 greatly reduced the 
propensity of the protein to form large aggregates and to precipitate. The cytotoxicity of 
E5-TAT-mCherry was also reduced when compared to HA2-TAT-mCherry and was 
comparable to that of TAT-mCherry. The E5-TAT tag therefore appears to be equivalent 
to TAT with regard to these properties.  
      While solving important aggregation and cytotoxicity problems, E5-TAT, like HA2-
TAT, did not appear to increase the delivery of its mCherry cargo. First, the lytic activity 
of E5-TAT-mCherry was significantly lower than that of E5-TAT itself. This is puzzling 
and understanding how the addition of a protein to the C-terminus of E5-TAT might 
affect the lytic activity of the peptide remains an important question to answer if one is 
to use this approach to deliver macromolecules. These observations suggest, however, 
that enhancing the lytic activity of the fusion tag would not be sufficient to achieve 
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delivery. For instance, addition of E5-TAT increased the number of cells in which 
dextran-fluorescein escaped from endosomes but did not increase the cytosolic delivery 
of E5-TAT-mCherry as the protein still remained localized at endosomes. The results 
suggest that this might be due to the affinity of E5-TAT for membranes. This membrane 
affinity was also illustrated by the extensive binding of E5-TAT-mCherry to the plasma 
membrane of HeLa cells and by the cytoplasmic retention of the microinjected protein.      
       Overall, these results suggest an important problem in the use of HA2 analogs as 
delivery tags for protein cargos. HA2 and HA2 analogs are designed to lyse endosomal 
membranes in a pH-dependent manner. This activity is linked to the amphipathic and 
helical nature of the peptide and membrane lysis involves a direct binding between the 
peptide and the endosomal lipid bilayer. However, the hydrophobicity of the peptide and 
its binding to membranes appears to lead to a failure in the delivery of the protein and a 
dramatic alteration of the protein’s intracellular behavior. This is the case not only for 
the hydrophobic and poorly behaved HA2 but also for E5, a tag with improved in vitro 
properties. On one hand, it is possible that tuning the properties of HA2 analogs or 
combining the peptides with other PTDs might solve this problem. On the other hand, 
data suggest that a solution might be to introduce linkers between the HA2-TAT delivery 
tag and its protein cargo that could be cleaved inside cells. Because the hemolytic 
activity of E5-TAT is far greater than that of E5-TAT attached to mCherry, an ideal 
linker would be one that is cleaved inside endosomes. Linker cleavage would therefore 
both induce an increase in the endosomolytic activity of E5-TAT but also release an 
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unperturbed protein that would be able to escape into the cytosol. The design of such 
systems will be the object of further studies. 
 
2.4 Materials & Methods 
2.4.1 Cloning and protein expression of HA2-TAT-mCherry and E5-TAT-mCherry 
     Cloning was designed to obtain a gene coding for a SUMO-HA2-TAT-mCherry 
construct in the pTXB1 vector (New England Biolab). The HA2 encoding 
oligonucleotides 5’-TAT GGG TCT GTT TGG TGC TAT CGC TGG TTT CAT CGA 
GAA CGG TTG GGA AGG TCA-3’ and 5’-TAT GAC CTT CCC AAC CGT TTT CGA 
TGA AAC CAG CGA TAG CAC CGA ACA GAC C-3’ were first annealed and inserted 
into a Nde-I digested pTXB1. A SUMO-HA2 gene was then constructed by overlap 
extension by PCR (polymerase chain reaction). The HA2 sequence was amplified by 
PCR of the pTXB1-HA2 vector with the primers 5’-CAC AGA GAA CAG ATT GGT 
GGT GGT CTG TTC GGT GCT ATC GCT-3’ and 5’-CTC CAG GCG GCC GCC ACC 
GTA CCA ACC ATC GAT CAT ACC TTC CCA-3’. The SUMO sequence was 
amplified by PCR of the pET SUMO vector (Invitrogen) with the primers 5’-GAT ATA 
CAT ATG GGT CAT CAC CAT CAT-3’ and 5’-CAG CGA TAG CAC CGA ACA 
GAC CAC CAC CAA TCT GTT CTC TGT G-3’. The SUMO and HA2 DNA fragments 
were combined, denatured, annealed, and extended by PCR with the primers 5’-GAT 
ATA CAT ATG GGT CAT CAC CAT CAT-3’ and 5’-CTC CAG GCG GCC GCC ACC 
GTA CCA ACC ATC GAT CAT ACC TTC CCA-3’ to obtain the recombined SUMO-
HA2 product. The SUMO-HA2 DNA was inserted into a NdeI and NotI digested pTXB1 
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to obtain pTXB1-SUMO-HA2. The oligonucleotides 5’-GGC CGC AAA AAA CGT 
CGT CAG CGT CGT CGT-3’ and 5’-GCA ACG ACG ACG CTG ACG ACG TTT TTT 
GC-3’ were annealed and ligated into NotI and SapI digested pTXB1-SUMO-HA2 to 
yield a pTXB1-SUMO-HA2-TAT product. The SUMO-HA2-TAT sequence was 
amplified by PCR with the primers 5’-GAT ATA CAT ATG GGT CAT CAC CAT CA-3’ 
and 5’-TGC ATC TCC CGT CAT ATG ACG ACG ACG CTG-3’. The PCR product was 
digested with NdeI and ligated into a previously described pTXB1-mCherry vector 
digested with NdeI.(78) The product obtained is pTXB1-SUMO-HA2-TAT-mCherry. It 
encodes for the protein SUMO-HA2-TAT-mCherry-GyrA-CBD, where GyrA is an intein 
and CBD a chitin-binding domain. Sequencing of the construct demonstrated the absence 
of mutations. The product pTXB1-SUMO-E5-TAT-mCherry was obtained by 
mutagenesis of pTXB1-SUMO-HA2-TAT-mCherry using the QuikChange site-directed 
mutagenesis kit and the primers. 
The plasmids were transformed into BL21-DE3 cells and protein expression was 
induced with 0.5 mM IPTG (isopropyl -D-1-thiogalactopyranoside) at 37C for 3 hr. 
Cells were harvested and resuspended in lysis buffer containing 20 mM Tris-Cl (pH 7.5) 
and 200 mM NaCl. After cell lysis by sonication and high-speed centrifugation at 15000 
rpm for 30 min, the soluble fraction was applied to chitin resin pre-equilibrated with lysis 
buffer and incubated overnight at 4C. The resin was washed with 8 column volumes of 
lysis buffer. The SUMO-HA2-TAT-mCherry and SUMO-E5-TAT-mCherry moieties 
were cleaved from the resin by incubation of the beads with 1 column volume of buffer 
supplemented with 100 mM DTT for 24 hr at room temperature. This cleavage step 
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yields a cleaved protein with a C-terminal carboxylate. The SUMO tag was removed with 
the SUMO protease with the molar ratio of 1: 25 (SUMO protease: protein). The proteins 
were purified by cation-exchange chromatography in 50 mM HEPES at pH 7 (HiTrap SP 
HP, GE Healthcare). The final products are HA2-TAT-mCherry and E5-TAT-mCherry. 
The protein mass was confirmed by MALDI-TOF (matrix-assisted laser 
desorption/ionization time of flight) mass spectrometry (AXIMA-CFR, Shimazu, Kyoto). 
Protein sequence analysis by automated Edman chemistry was performed by the Protein 
Chemistry Laboratory at Texas A&M University to further confirm that the N-terminus 
of HA2 and E5 were properly generated. The N-terminal sequence was identified as 
GLFGAIA and GLFEAIAEFI with 99% confidence for HA2-TAT-mCherry and E5-
TAT-mCherry, respectively. 
 
2.4.2 Electron microscopy 
       Specimens were prepared by adding 5l of sample (0.04-0.08 mg/ml in 20 mM Tris 
pH 7.8, 150 mM NaCl) onto freshly glow-discharged formvar-carbon coated grids and 
left to adhere for 1 minute. Specimens were then stained for 15 seconds in either 2% 
aqueous uranyl acetate (pH 4.5) or 2% sodium phosphotungstate (pH 7.0) and blotted 
dry. Specimens were observed on a JEOL 1200EX transmission electron microscope 
operating at an acceleration voltage of 100kV. Images were recorded at calibrated 
magnifications on KODAK 4489 film. 
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2.4.3 Analytical ultracentrifugation 
      Samples were analyzed by sedimentation velocity ultracentrifugation using a 
Beckman XLA centrifuge with an An60Ti rotor. Standard double-sector aluminum 
centerpiece cells with quartz windows and a 1.2 cm optical pathlength were used. 
Protein loading concentrations were 2–8 M. Centrifugation was at 28,500 rpm and 
25°C with absorbance scans at 280 nm taken at 3.5 min intervals. The absorbance scans 
were fit to a single sedimentation coefficient by using the computer program Svedberg 
from John Philo, with the uncertainties given as the 95% confidence intervals (79). 
 
2.4.4 Microinjection of mCherry and TAT-mCherry into live cells 
       HeLa were cultured on 35 mm plates (P35G-1.5-7-C-grid, MatTek Corp., Ashland, 
MA) at 100,000 cells/mL in a total volume of 2 mL of Dulbecco’s modified Eagle’s 
medium supplemented with 10% FBS in a humidified atmosphere containing 5% CO2. 
Cells were washed and incubated with Leibovitz’s L-15 Medium and placed on the 
microscope. mCherry or TAT-mCherry (10 M) were mixed with 70 kDa Dextran-
fluorescein (10 M) and femtoliter aliquots were directly injected into the cytoplasm of 
live HeLa cells using an InjectMan NI2 micromanipulator equipped with a FemtoJet 
microinjector (Eppendorf, Westbury, NY). The microinjected cells were imaged for up to 
3 h after microinjection. Microinjection into the cytoplasm rather than nucleus was 
confirmed by observing nuclear exclusion of the 70 kDa Dextran. The localization of the 
nucleus within the injected cells was also confirmed by staining with the cell-permeable 
nuclear stain Hoecht 33342 (Molecular Probes, Carlsbad, CA).
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2.4.5 Binding assay 
 The binding of E5-TAT-mCherry to intact RBCs as a function of pH was 
determined by incubating peptide (1 M) with 1.25% RBC suspensions in PBS at 
different pH values (adjusted with HCl or NaOH, 4.5<pH<7.5). After 5 min incubation, 
the samples were centrifuged for 5 minutes at 1500g. The amount of peptide present in 
the supernatants was analyzed by SDS-PAGE (sodium dodecyl sulfate polyacrylamide 
gel electrophoresis) using 12% SDS-gel (pH 8.8). The gels were stained with coomassie 
and densitometric analysis of the intensity of the E5-TAT-mCherry bands was 
performed with the ImageQuant 5.0 software. The data were normalized using a sample 
containing E5-TAT-mCherry at pH 7.0 but with no RBC present as the one hundred 
percent soluble control.  
 
2.4.6 Hemolysis assays 
A membrane lysis assay was performed with human erythrocytes purchased from the 
Gulf blood bank (Galveston, TX). Erythrocytes were centrifuged for 5 min at 1500g. 
The erythrocyte pellet obtained was resuspended in PBS and this procedure was repeated 
three times to remove the plasma and buffy coat. The erythrocytes (resuspended in PBS 
to a 50% suspension) were then diluted 20 fold in PBS of different pH values (adjusted 
with HCl or NaOH, 4.5<pH<7.5). All proteins were diluted with PBS to desired 
concentrations and added to a 96-well plate. One hundred microliters of the 2.5% RBC 
suspension was added into each well. The plates were incubated at 37C for 30 min. 
After centrifuging the plate for 5 minutes at 1500g, the supernatants were transferred to a 
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new 96-well plate. The absorbance of hemoglobin present in each well was measured at 
450 nm using a plate reader (Bio-RAD, Ultramark Micro plate system, USA). One 
hundred percent hemolysis was obtained by incubating the RBC with 0.1% Triton X-100. 
Background hemolysis at various pH was evaluated by incubating the erythrocytes in the 
corresponding PBS solutions. The background signal from mCherry was also estimated 
by analyzing the absorbance of samples containing the proteins ate the desired 
concentration but no RBCs. 
2.4.7 Microscopy assays 
 HeLa cells were seeded on 8-well chamber glass slide at 3.0 x 104 cells/well in 
Dulbecco’s modified Eagle’s medium supplemented with 10% FBS and incubated for 24 
h at 37°C in a humidified atmosphere containing 5% CO2. Cells were then incubated with 
L-15 medium (no FBS added) and placed on an inverted epifluorescence microscope 
(Model IX81, Olympus, Center Valley, PA) equipped with a heating stage maintained at 
37°C. The microscope is configured with a spinning disk unit to perform both confocal 
and wide-field fluorescence microscopy. Images were collected using a Rolera-MGI Plus 
back-illuminated EMCCD camera (Qimaging, Surrey, BC, Canada). Images were 
acquired using phase contrast and three standard fluorescence filter sets: CFP (Ex = 
43620 nm / Em= 48040 nm), Texas Red (Ex = 56040 nm / Em= 63075 nm), and 
FITC (fluorescein isothiocyanate) (Ex = 48235 nm / Em= 53640 nm). Cells were co-
treated with of HA2-TAT-mCherry or E5-TAT-mCherry (2 M) in L-15 medium 
containing 2.5 mg/mL of 70 kDa anionic dextran-fluorescein (78). After incubation at 
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37°C for 15 or 60 minutes, the cells were washed with PBS 5 times and the medium was 
replaced with fresh L-15. The integrity of the plasma membrane of the cells was 
determined by addition of the cell-impermeable DNA stain SYTOX Blue. Cells with a 
blue fluorescent nucleus, detected with the CFP filter set, were considered compromised 
or dead. The cells that were not stained by SYTOX Blue were further confirmed to be 
alive by detection of active transport of intracellular endocytic vesicles. To inhibit cell 
surface binding of the delivery peptides, heparin sodium salt (1 mg/mL) was added 
during the co-incubation step. For the inhibition of macropinocytosis, cells were first 
pretreated with 50 M of amiloride (Sigma, MO) for 30 minutes, and then with E5-TAT-
mCherry and 70 kDa dextran-fluorescein while keeping amiloride present. To inhibit 
acidification of the endolysosomal organelles, bafilomycin (200 nM) was used in a 
similar protocol. Cells were then co-incubated with E5-TAT-mCherry and 70 kDa 
dextran-fluorescein in L-15 supplemented with bafilomycin (200 nM). The fluorescence 
intensities within cells were measured using the SlideBook 4.2 software (Olympus, 
Center Valley, PA).  
 HA2-TAT-mCherry and E5-TAT-mCherry were added to the 1.25% RBC 
suspension in PBS at pH 4.5 or 7 by dilution from their PBS stock to the desired final 
concentration. After incubation at 37°C for 20 minutes, two hundred microliters of these 
suspensions were added to the wells of an 8-well chamber glass slide (Nunc). Cells were 
placed on an inverted epifluorescence microscope (Model IX81, Olympus, Center 
Valley, PA) equipped with a heating stage maintained at 37°C. Cells were typically 
allowed to settle to the bottom of the dish for 5 minutes prior to imaging so as to obtain a 
45 
 
layer of cells in the focal plane. To wash ghosts, 200 L of 2.5% RBC suspension with 
the hemolytic peptides were centrifuged for 5 minutes at 1500g. The supernatant was 
removed and cells were resuspended in 200 L fresh PBS at a desired pH. A 20 L 
aliquot of the cells was added to an 8-well glass slide and imaged to monitor the 
morphology and fluorescence of cells. These steps were repeated 3 to 5 times, or until 
spherical ghosts could not be recovered.  
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3. DELIVERY OF MACROMOLECULES INTO LIVE CELLS BY SIMPLE CO-
INCUBATION WITH HA2- TAT* 
 
3.1 Introduction 
 In Section 2, it has been shown by hemolysis assay that covalently linked E5TAT-
mCherry exhibits pH-dependent lipid membrane disruption activity. This result indicates 
that E5TAT-mCherry could enhance endosomal release compared to TAT-mCherry 
alone. However, the hydrophobic property of HA2 sequence causes the whole protein 
tag to associate with the endosomal vesicle instead of escaping from endosomes. In 
addition, even when TAT-mCherry was released from endosomes, TAT caused the 
protein to accumulate within nucleoli. In summary, using covalently linked CPP-
conjugated cargos for delivery is straightforward; yet CPPs may alter the native cellular 
localization and bioactivity of conjugated protein. Therefore, co-incubation delivery of 
CPPs and cargo protein is examined in this study. Dowdy and coworkers have shown 
that the cytosolic delivery of a TAT-Cre recombinase construct could be increased by 
co-incubation with a HA2-TAT conjugate. In this example, the increase in cytosolic 
targeting was demonstrated by measuring the biological activity of the delivered protein 
inside the cell. However, the delivery efficiency of HA2-TAT is mostly uncharacterized.     
 In Section 3,  I am going to test  the hypothesis  that optimized  CPPs  might deliver  
______________  
*Part of this section is reprinted with permission from Delivery of macromolecules into live 
cells by simple coincubation with a peptide by Lee YJ, Erazo-Oliveras A, Pellois JP 
Chembiochem. 2010 Feb 15;11(3):325-30., Copyright 2010 by John Wiley & Sons, Inc. 
http://onlinelibrary.wiley.com/doi/10.1002/cbic.200900527/full 
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macromolecules to the cytosol of live cells by simple co-incubation without the 
promotions of increased levels of endocytosis (41,80,81). We therefore reasoned that a 
CPP might induce a cell to drink-up macromolecules present in its surrounding media 
and that CPPs and macromolecules might accumulate together inside endocytic 
organelles. A CPP capable of disrupting these endocytic organelles might then induce 
the release of the macromolecules into the cytosolic space.  
 Importantly, macromolecules would not have to be modified with the CPP, and any 
undesired effect of the CPP on the macromolecule’s function or localization after 
delivery would be avoided. Although this co-incubation protocol might not be suitable 
for the delivery of molecules in therapeutic applications, it would be simpler and less 
invasive than other multistep delivery processes (e.g., osmotic lysis of pinocytic vesicles, 
plasma membrane permeabilization, scrape loading, or microinjection). Therefore this 
protocol represents a step towards making macromolecule delivery into cultured cells a 
routine procedure for imaging or cell biology applications. 
 
3.2 Results 
3.2.1 HA2-TAT cytotoxicity
      To identify an effective concentration of CPP that could be used for the delivery of 
macromolecules without inducing cell death, the cytotoxicity of these peptides E3-TAT 
(D19E mutation form wild type HA2 from SPPS, solid phase peptide synthesis purpose), 
E5-TAT and TAT toward HeLa cells was first examined by using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay (Fig. 3-1) and by 
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observation of the cell morphology by phase-contrast imaging. Cells were exposed to the 
CPPs at different concentrations for 1 h, washed and incubated in L-15 media from 3 to 
24 h before being assayed for viability. The results showed that TAT was essentially 
noncytotoxic under the conditions tested (1–20 M) according to the MTT assay. 
However, above 10 M, the peptide appeared to affect the morphology of a large 
population of cells. E3-TAT and E5-TAT did not induce a significant decrease in cell 
viability at concentrations below 2.5 M. In contrast to TAT, the cytotoxicity of the 
peptides were, however, more acute at 5 mm and above. Overall, to minimize the 
physiological effects that the peptide might have on cells, concentrations of 10 M of 
TAT and 2 M of E3-TAT and E5-TAT were therefore set as upper limits for testing the 
delivery of fluorescent cargos to live cells. 
 
3.2.2 HA2-TAT  promote  cellular  uptake  and  endosomal  escape  of  co-incubated
         fluorescent cargos 
      To characterize the CPP-mediated delivery of macromolecules in live cells, 
fluorescent dextrans and proteins were chosen as model cargos, including 10 and 70 kDa 
anionic Dextran-fluorescein, 10 and 70 kDa neutral Dextran-tetramethylrhodamine, 70 
kDa neutral Dextran-Texas Red, the green fluorescent protein EGFP (27 kDa, pI=5.7, -7 
charges at pH 7.2), and the red fluorescent proteins mCherry (28 kDa, pI=6.0, -4 charges 
at pH 7.2), MBP-mCherry (71 kDa, pI=5.5, -10 charges at pH 7) and tdTomato (55 kDa, 
pI=6.3, -6 charges at pH 7.2) (82). These molecules have different sizes and overall 
within  the  cells. Genetically  encoded  fluorescent  proteins  were tested  because  these  
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Figure 3-1 Viability of HeLa cells incubated with TAT, E3-TAT, or E5-TAT. Cells 
were treated with the peptides for 1 h, washed, and incubated in fresh media for an 
additional 3 h. Viability is measured as a function of peptide concentration by using the 
MTT assay. 
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charges as well as different chemical structures that might affect uptake and localization 
proteins lose their fluorescence if unfolded or proteolytically cleaved (78). Detection of 
their fluorescent emission inside a cell therefore serves as an indication that the proteins 
are not degraded. On the other hand, their fluorescent signals might disappear with time 
if the proteins remain trapped inside degradative organelles such as lysosomes. Dextrans 
are typically resistant to intracellular degradation, including degradation within the 
endolysosomal pathway (83). As a result, dextran–tetramethylrhodamine and dextran–
Texas Red provide useful markers to measure and compare the endocytic or cytosolic 
distribution of fluorescent material internalized into a cell. (Fluorescein is pH sensitive 
and its fluorescence is partially quenched in the acidic lumen of endocytic organelles but 
tetramethylrhodamine and Texas Red are relatively insensitive to pH) (78). When co-
incubated with the different fluorescent cargos, TAT, E3-TAT, and E5-TAT did not 
affect the fluorescence emission or anisotropy of the various fluorescent molecules 
tested; this indicates that the peptides do not bind to the cargos at detectable levels. 
Native-gel-electrophoresis analysis of the peptide/protein mixtures further confirmed 
that while TAT might bind to negatively-charged proteins to generate low concentrations 
of peptide/protein complexes, E5-TAT does not appear to interact with the fluorescent 
proteins tested at detectable levels (Figs. 3-2 and 3-3).  
       In a typical cell-based delivery assay, the CPPs (2M) were incubated with two 
fluorescent cargos, one larger and one smaller than the nuclear diffusion threshold (~50 
kDa) (76). Cell viability during these assays was determined by using SYTOX blue 
staining, and by observation of active transport of intracellular endocytic organelles with 
51 
 
time-lapse imaging (Fig. 3-4). HeLa (human cervical adenocarcinoma), COS-7 (SV40 
transformed African green monkey kidney fibroblast-like cell line), and COLO 316 
(human ovarian carcinoma) cells were incubated with the fluorescent macromolecules 
(10 M for the proteins, 2.5 mg/mL for the dextrans, or approximately 250 M and 36 
M for 10 kDa and 70 kDa dextrans, respectively), in combination with a CPP (2 M) 
for 1 h. After washing the cells, internalization of the fluorescent material was imaged 
by live-cell fluorescence microscopy.  
 Under the conditions tested, cells incubated with just the macromolecules and no 
CPP displayed an intracellular punctate distribution of fluorescent markers of relative 
low fluores-cence intensity. This distribution is consistent with internalization of the 
fluorescent markers by fluid-phase endocytosis at basal level. The markers then remain 
trapped inside endocytic organelles. In contrast, cells incubated with the CPPs 
partitioned into two distinct populations: cells with a punctate labeling and cells with 
diffusely distributed fluorescent cargos. (These two populations are illustrated by the 
left-side image of Fig. 3-5A on p.56. Please note that 100% of the cells contained the 
fluorescent macromolecules but that fluorescence is either localized inside endocytic 
organelles or distributed throughout the cell). Nuclear exclusion of the large cargo 
served as a demonstration that the fluorescent signal observed was indeed intracellular 
rather than out-of-focus fluorescence of the cargos bound to the plasma membrane 
(right-side image in Fig. 3-5A on p.56, the nucleus is labeled with the 10 kDa dextran–
fluorescein but not with the larger 70 kDa dextran–Texas Red). When TAT was used as 
delivery  peptide, the  population of  the  cells  containing  a  diffused distribution of  the 
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Figure 3-2 Non-covalent binding interaction between the delivery peptides and serum 
proteins. Fluorescein labeled TAT or E5-TAT was incubated in L-15 with or without 
10% FBS and interaction were detected by native gel electrophoresis. The protein bands 
were detected by coomassie staining while the presence of protein-bound peptides was 
detected by the fluorescence signal of fluorescein. Fl-TAT binds to serum proteins 
(including BSA, bovine serum albumin) at 50 M or more while no binding is observed 
for Fl-E5-TAT. 
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Figure 3-3 Non-covalent binding interactions between the delivery peptides and the 
proteins BSA (a) or mCherry (b). Fluorescein labeled TAT or E5-TAT was incubated in 
L-15 with the proteins at different ratio and interactions between peptides and proteins 
were detected by native gel electrophoresis. a) The protein bands were detected by 
coomassie staining for BSA (the BSA dimer and larger oligomers can be observed) 
while the presence of protein-bound peptides was detected by the fluorescence signal of 
fluorescein. Fl-TAT appears as a smear in lane 2 and 3. A smear is also present in lane 6 
for Fl-E5-TAT (the fluorescence intensity is approximately 10% that of Fl-TAT). b) The 
protein bands were detected by the red fluorescence emission of mCherry while the 
presence of protein-bound peptides was detected by the green fluorescence signal of 
fluorescein. mCherry labeled with fluorescein (b, lane 7) was used as a control to 
validate that both mCherry and fluorescein fluorescence could be detected. Lane 7 is 
black with a white area in the center because the fluorescence signal is so high in the 
white area that the detector is saturated. 
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Figure 3-4 Effects of E5-TAT and mCherry co-incubation on cell viability. HeLa cells 
were treated with E5-TAT or E5-TAT + mCherry for one hour. After washing, the cells 
were treated with SYTOX Blue so as to detect dead cells or cells with a compromised 
plasma membrane. Cells were then imaged by phase contrast and fluorescence 
microscopy for 4 hours. a) Images of different cell samples. Phase contrast (colored 
grey), SYTOX Blue (pseudocolored blue), and mCherry (pseudocolored red) images 
were overlayed. Dead cells can be identified by their blue nucleus and cells with 
mCherry distributed in their cytosolic space are red. Note that the red cells in the 
“sample 2” image do not have a blue nucleus, thereby confirming that these cells are 
alive. b) Cell viability was measured by counting the cells containing a blue nucleus 
(dead cells) and the total cell number from the phase contrast image. Cell viability is 
reported for each sample as a percentage relative to the control consisting of untreated 
cells. 
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than 1% of the total cells observed. (That is, more than 99 % of cells contain the 
fluorescent macromolecules in endocytic vesicles). No significant differences were 
observed regardless of the concentration tested (1–10 mm). In contrast, the number of 
cells with a diffuse cytosolic distribution was 8 2% and 15%3% on average in cases in 
which E3-TAT and E5-TAT were used, respectively (2 M, Fig. 3-6A , the results 
represent mCherry and are comparable to the other macromolecules tested, see Fig. 3-7). 
Based on the measurement of the fluorescence intensities, the cytosolic/nuclear signals 
of cells with a diffuse distribution were 50-fold above that of cells with a punctate 
distribution. Similar results were obtained HeLa, COS-7 or COLO 316 cells (Fig. 3-5 B).  
 
3.2.3 HA2-TATs promote cellular uptake through endocytic pathway 
  The total fluorescence intensity of cells incubated with the macromolecules and TAT, 
E3-TAT or E5-TAT were three- to fivefold higher than that of cells incubated without 
delivery peptides; this indicates that increased levels of cellular uptake had been induced 
by the peptides (Fig.s 3-6B and 3-7, the fluorescence intensities of whole cells are 
measured to estimate the average amount of fluorescent material internalized inside 
cells). Internalization of the fluorescent cargos into endocytic organelles was inhibited at 
4?; this indicates that uptake is an energy-dependent process. Internalization was also 
inhibited by heparin, a molecule known to inhibit the binding of TAT to heparan sulfate 
proteoglycans or other negatively charged molecules present on the cell surface (Fig. 3-
6A) (84). This is consistent with previous mechanistic studies of TAT-mediated uptake 
and suggests  that the TAT moiety in E3-TAT or E5-TAT is in large  part responsible for 
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Figure 3-5 Live-cell imaging of cells incubated with E5-TAT, green and red fluorescent 
macromolecules. A) After a 1 h incubation with E5-TAT, a green and a red fluorescent 
dextran, HeLa cells display diffuse and punctate distribution of the fluorescent 
macromolecules. The fluorescence images acquired in the green and red channels are 
pseudo-colored and overlayed. Colocalization of the green and red fluorescence signals 
results in a yellow color in the overlay image. The perimeter of the cells is highlighted in 
the left-hand side image, while the cytosolic and nuclear spaces are indicated by white 
arrows in the right-hand side image. The 10 kDa green dextran diffuses into the nucleus, 
while the 70 kDa red dextran does not and the nucleus appears green. B) Delivery of the 
protein mCherry and of 70 kDa dextran– fluorescein in different cell lines. The protein 
diffuses into the nucleus, while the 70 kDa green dextran does not and the nucleus 
appears red. 
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Figure 3-6 Effects of co-incubation conditions and inhibitors on the delivery of the 
protein mCherry to HeLa cells.   
 
Figure 3-7 Effects of co-incubation conditions and inhibitors on the delivery of 70kDa 
Dextran-Texas Red to HeLa cells. 
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the elevated endocytic uptake of the cargos (80). The vacuolar H+-ATPase inhibitor 
bafilomycin was used to inhibit endosomal acidification prior to incubation with E3-
TAT or E5-TAT and the fluorescent cargos (70). The number of cells containing a 
diffuse distribution of fluorescent cargos was greatly reduced by this treatment from 8 or 
15% to less than 0.5% (Fig. 3-6 A). The amount of material internalized was however 
unchanged based on the fluorescence intensities of cells containing a punctate 
distribution of cargos (Fig. 3-6 B). This indicates that the presence of cells with diffusely 
distributed fluorescent cargos is dependent on the acidification of the lumen of endocytic 
organelles and that E3-TAT and E5-TAT mediate endosomal release through their pH-
dependent membrane-disruption activity. 
 
3.2.4  PAD  delivered  by  HA2-TAT   and   induces   apoptosis   through   endocytic
          pathway 
   To determine whether E5-TAT could mediate the delivery of a biologically active 
cargo, the delivery of the proapoptotic domain (PAD) peptide KLAKLAKKLAKLAK-
NH2 into HeLa cells was evaluated (85,86). If present inside cells, PAD has been shown 
to induce apoptosis by triggering mitochondrial permeabilization and depolarization (86). 
However, PAD cannot cross the plasma membrane by itself and shows low cytotoxicity 
in in vitro assays in cases in which no delivery agent is used (86). In this assay, PAD 
was therefore co-incubated with TAT or E5-TAT, and cell viability, evaluated with the 
MTT assay, was used as an indirect measure of the efficiency with which PAD reaches 
the cytosolic space and the mitochondria. As shown in Fig. 3-8A, co-incubation of TAT 
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(5 M) with PAD (20 M) did not cause more cell death than treatment with PAD (20 
M) alone; this suggests that TAT is not able to deliver PAD efficiently. In contrast, 
addition of increasing concentrations of E5-TAT to PAD induced an increase in cell 
death. In order to confirm that the cytotoxicity levels observed were due to an increase in 
delivery of PAD into cells by E5-TAT as opposed to non delivery-related effects of the 
combined peptides, this assay was also performed with cells treated with amiloride. 
Amiloride is an inhibitor of macropinocytosis, a form of endocytosis known to be 
important for the uptake of TAT-cargo conjugates into cells (80,87,88). I therefore 
reasoned that macropinocytosis could be involved in the uptake of E5-TAT and that 
inhibition of macropinocytosis might fully or partially block E5-TAT-mediated delivery 
of PAD. In agreement with this idea, cell death was significantly reduced upon amiloride 
treatment. These results therefore suggest that inhibition of macropinocytosis reduces the 
delivery of PAD into cells and that the cytotoxicity effects observed are in great part due 
to the E5-TAT-mediated delivery of a bioactive PAD into the cells. (The cytotoxicity 
observed in the presence of amiloride could be caused by incomplete inhibition of the 
transport of PAD; it is also consistent with the cytotoxicity observed for E5-TAT alone 
as shown in Fig. 3-1). These results were further confirmed by using fluorescence 
microscopy to monitor the delivery of a PAD peptide labeled with the red fluorophore 
carboxytetramethylrhodamine, TMR-PAD. Cells incubated with both TMR-PAD and 
E5-TAT displayed a cytoplasmic red fluorescence emission consistent with delivery of 
PAD into their cytoplasm (Fig. 3-8 B), while cells treated with TMR-PAD alone did not. 
stain  approximately 30 min after incubation  with the peptides was completed. The cells 
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Figure 3-8 Delivery of the proapoptotic peptide domain PAD into live cells by co-
incubation with E5-TAT. A) PAD (20 M) and TAT or E5-TAT (3 to 7 M) were added 
to the cell culture media for 1 h. Delivery of the bioactive PAD was assessed by 
measuring the level of cell death caused by this incubation. Addition of E5-TAT to PAD 
results in an increase in cell death while addition of TAT does not. Inhibition of 
macropinocytosis by treatment of the cells with amiloride reduces cell death. These 
results therefore suggest that inhibition of macropinocytosis reduces the delivery of PAD 
into cells and that the cytotoxicity effects observed are in great part due to the E5-TAT-
mediated delivery of a bioactive PAD into the cells. B) Delivery of the red fluorescent 
TMR-PAD by E5-TAT detected by microscopy. The phase contrast and fluorescence 
images acquired in the blue (SYTOX Blue detection) and red channels (TMR-PAD 
detection) are pseudo-colored and overlayed. Cells showing a cytosolic distribution of 
TMR-PAD become permeable to SYTOX Blue over time (blue nuclei shown) and 
apoptotic. This indicates that delivery of PAD precedes cell death and is consistent that 
the idea that PAD causes apoptosis. Please note that the blue areas in the first image are 
due to the nuclear debris of cells that have died during the incubation with the peptides 
and that are stained by SYTOX Blue. 
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containing the red fluorescent PAD became permeable to the SYTOX blue DNA also 
displayed marked changes in their morphology consistent with apoptosis, including 
membrane blebbing, contraction, and nuclear fragmentation. Importantly, cells without 
red fluorescence were not stained by SYTOX blue. In addition, the control peptide 
TMR-K9 was also delivered into the cytosol of cells by E5-TAT co-incubation. These 
cells did not become apoptotic or permeable to SYTOX Blue (see Fig. 3-4 for similar 
experiments performed with mCherry). These results indicate that delivery alone does 
not cause cell death but that the cytotoxicity observed is a result of the activity of PAD. 
Because cells containing TMR-PAD died during the experiment, an exact quantification 
of the delivery efficiency could not be determined by microscopy. However, based on 
the MTT assay, it appears that E5-TAT was able to deliver a lethal dose of active PAD 
to 15– 25% of cells (Fig. 3-8A), as established by the difference in cell viability 
observed between the cells with or without amiloride.  
 
3.3 Discussion 
 Overall, these results suggest that TAT performs poorly for the delivery of 
macromolecules in trans. Addition of endosome disrupting peptides E3 or E5, however, 
enhances the activity of the peptide and a significant fraction of cells containing 
macromolecules in the cytosolic and nuclear spaces can then be observed. E3/5-TAT 
delivery is mediated by endocytosis and endosomal release, rather than by direct 
translocation across the plasma membrane (Fig. 3-9). First, the TAT moiety binds to the 
cell surface and induces an increase in endocytic uptake. Macromolecular cargos present 
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in the media surrounding the cell are then internalized along with the delivery peptide 
into endosomes. Upon progressive acidification of the lumen of endosomes, the E3/E5 
moiety disrupts the endosomal membrane and the cargos escape into the cytosol. E5 is 
known to induce membrane leakage more actively than E3, and consistent with this 
observation, E5-TAT appears to deliver fluorescent cargos into cells more efficiently 
than E3-TAT. 
  Multiple macromolecules with very different size, charge, hydrophobicity, and 
chemical structures could be delivered simultaneously to the cell when co-incubated 
with E5-TAT. This, along with the fact that no binding interactions between E5-TAT 
and the macromolecules tested could be detected in vitro assays (fluorescence assays and 
native gel electrophoresis, (Fig. 3-3) suggests that binding of E5-TAT to a 
macromolecule is not required to achieve delivery. As a result, no chemical or genetic 
modification of the cargo is required, and this thereby allows for a simple “mix and 
incubate” protocol to be performed. Moreover, the function of the delivered 
macromolecule is not altered by the delivery peptide once delivery is achieved. 
Preliminary delivery experiments with HA2-TAT–mCherry, a macromolecule in which 
the delivery peptide HA2-TAT is fused to the mCherry cargo, established that the 
membrane affinity of the HA2-TAT moiety promotes binding of mCherry to 
intracellular membranes and that, as a result, the protein remains tethered to endosomes 
and is able to escape into the cytosolic space. This further emphasizes that, at least for in 
vitro assays, a “nonconjugation” approach might be preferable. It should be noted 
however  the  E5-TAT delivery method  presented herein  could involve the noncovalent 
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Figure 3-9 Proposed model for the delivery of macromolecules mediated by co-
incubation with E5-TAT. Delivery occurs in a two-step process: endocytosis followed 
by endosomal release. TAT is primarily responsible for the internalization of molecules 
present in the incubation media by endocytosis while E5 induces escape of the content of 
endocytic organelles into the cytosolic space. The represented stoichiometry of E5-TAT 
versus macromolecules is arbitrary. 
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binding of the peptide to its cargo depending on the nature of themacromolecule used for 
delivery. Although no binding was detected for the various cargos used in this report 
(Fig.3-3), it is conceivable that highly negatively charged species (proteins with low 
isoelectric point, RNA, DNA) might interact with the arginine-rich TAT through 
multiple electrostatic interactions (Fig.s 3-2 and 3-3). However, it is also possible that 
such noncovalent interactions might induce a more efficient delivery. Delivery by co-
incubation with E5-TAT might therefore serve as a general approach, whether or not 
noncovalent interactions are involved between peptide and cargo. 
 In terms of applications, the activity of E5-TAT was sufficient to deliver imaging 
agents at a level that was well above the detection limit of a standard fluorescence 
microscopy set-up. A limitation however is the relatively low frequency of cells 
containing a clear diffuse distribution of the fluorescent agents. Although this might be 
suitable for certain assays (e.g., 15% of several thousand cells is many more cells than 
would be obtained by microinjection), it is inconvenient as it renders the imaging of 
multiple cells in the field of observation unlikely at high magnification. Future 
improvements should therefore be directed at increasing this aspect of the peptide’s 
activity. Interestingly, the E5-TAT delivery appeared to be an “all or none” process in 
which cells are distributed between two distinct populations: either the cargo reaches the 
cytosol with little appearing to be left inside endosomes or it almost completely remains 
trapped in numerous endocytic organelles. Understanding the phenomena will likely 
involve further characterization of how the peptide functions. In particular, it is possible 
that E5-TAT and the internalized macromolecules partition into different endocytic 
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organelles during or soon after uptake, thereby reducing the overall effectiveness of the 
delivery. In principle, other TAT-like molecules that could trigger different endocytic 
mechanisms of uptake combined to HA2-like moieties with greater endosomolytic 
activites might solve this problem and provide more efficient and general delivery 
systems. 
 
3.4 Materials & Methods 
3.4.1 Peptide synthesis
  E3-TAT, E5-TAT, and Fl-E5-TAT were purchased as crude cleavage products from 
RayBiotech (Norcross, GA). TAT, Fl-TAT, PAD (CKLAKLAKKLAKLAK), and TMR-
PAD (TMR-CKLAKLAKKLAKLAK) were synthesized in-house on the Rink amide 
resin by SPPS using standard Fmoc protocols. Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, 
Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, 
and Boc-Cys(StBu) were used to assemble the peptides and were purchased from 
Novabiochem (San Diego, CA). Reactions were carried out in SPPS vessels at room 
temperature using a stream of dry N2 to provide agitation. Fmoc deprotection was 
performed by addition of piperidine in DMF (dimethylformamide) (20%, 5 mL) to the 
Fmoc-peptide resin (0.72 mmol). Deprotection was carried out for 1×3 min and 1×10 
min. Coupling 2 reactions were carried out for 2 h with a mixture of Fmoc-amino acid 
(2.88 mmol), HBTU (2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate) (1.06 g, 2.80 mmol), and DIEA (N,N-Diisopropylethylamine) 
(1.25 mL, 7.2 mmol) in DMF. Upon completion of the reaction, the resin was washed 
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with DMF. For Fl-TAT, the Fmoc protecting group at the N-terminus of TAT was 
cleaved and the resin was washed with DMF. A mixture of 5,6-carboxyfluorescein and 
HBTU (2 and 1.9 equivalents in respect to the peptide) in DMF was added to the resin 
and the reaction was carried out overnight with gentle shaking. Following chain 
assembly, the resins were washed with dichloromethane and dried in vacuo. The resin 
was then treated with TFA (Trifluoroacetic acid) containing 2.5% H2O and 2.5% 
triisopropylsilane, for 3 hour at room temperature to achieve global deprotection and 
cleavage from the support. The crude peptide products were precipitated and washed 
with cold anhydrous Et2O. The precipitates were resuspended in water and lyophilized. 
The powdery products obtained were then resuspended in 0.1% aqueous 
TFA/acetonitrile. The peptides were analyzed and purified by reverse phase HPLC. 
HPLC analysis was performed on a Hewlett-Packard 1200 series instrument and a 
Vydac C18 column (5 micron, 4 x 150 mm). Flow rate was 1 mL/min and detection was 
at 214 nm. Semi-preparative HPLC was performed on a Vydac C18 10 × 250 mm 
column. Flow rate was 4 mL/min and detection was at 214 nm. All runs used linear 
gradients of 0.1% aqueous TFA (solvent A) and 90% acetonitrile, 10% water and 0.1% 
TFA (solvent B). To synthesize TMR-PAD, Fmoc-Cys(StBu) was added to the N-
terminus of PAD. The StBu group was cleaved by treatment with 3 tributyl phosphine, 
water, in DMF/DCM (1:1:4:4 volumes). Purified C-PAD (0.3 mg, 0.2 mol) was then 
reacted with 5(6)-tetramethylrhodamine-maleimide (0.13 mg, 0.2 mol, Anaspec, CA) in 
500 L of HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer (25 mM, 
pH 7.5) containing TCEP (tris(2-carboxyethyl)phosphine) (20 mM) as a reducing agent. 
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The formed TMR-PAD product was purified by HPLC. The correct identity of the 
peptides was confirmed by MALDI-TOF mass spectrometry (AXIMA-CFR, Shimazu, 
Kyoto). All purified and lyophilized peptides were dissolved to 1 mM in DMSO and 
diluted with PBS to desired concentrations in further experiments. TAT (H-
GRKKRRQRRR-NH2) expected mass: 1395.7 Da, observed mass: 1395.5 Da. 
Fluorescein-TAT (Fl-GRKKRRQRRR-NH2) expected mass: 1754.0 Da, observed mass: 
1754.5 Da. E3-TAT (H-GLFGA IAGFI ENGWE GLIEG WYGGR KKRRQ RRR-NH2) 
expected mass: 3834.4 Da, observed mass: 3835.7 Da. E5-TAT (H-GLFEA IAEFI 
ENGWE GLIEG WYGGR KKRRQ RRR-NH2) expected mass: 3978.5 Da, observed 
mass: 3978.8 Da. Fluorescein-E5-TAT (FITC-GLFEA IAEFI ENGWE GLIEG 
WYGGR KKRRQ RRR-NH2) expected mass: 4596.5 Da, observed mass: 4593.8 Da. 
PAD (H-KLAKLAKKLAKLAK-NH2) expected mass: 1523.0 Da, observed mass: 
1524.6 Da. C-PAD (H-CKLAKLAKKLAKLAK-NH2) expected mass: 1626.15 Da, 
observed mass: 1625.6 Da. TMR-PAD (H-C(TMR)KLAKLAKKLAKLAK-NH2) 
expected mass: 2107.6 Da, observed mass: 2108.5 Da. 
 
3.4.2 Cytotoxicity assay 
HeLa cells were seeded on 96-well tissue-culture plates at 1.0X104 cells per well. 
After incubation in a humidified atmosphere containing CO2 (5%) for 24 h at 378C in 
Dulbecco’s modified Eagle’s medium supplemented with fetal bovine serum (FBS, 
10%), the cells were washed with Leibovitz’s L-15 medium and treated with TAT, E3- 
TAT, and E5-TAT in L-15. After 1 h incubation, the cells were washed with fresh L-15 
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medium and incubated at 37 for 3 h. The number of live cells present in each well was 
then determined by using the Vybrant MTT Cell Proliferation Assay Kit (Molecular 
Probes). Alternatively, SYTOX Blue, a nucleic acid fluorescent stain that only 
penetrates cells with compromised plasma membranes, was used to measure cell 
viability by fluorescence microscopy imaging. 
3.4.3 Live cell assay 
For the transduction of fluorescent imaging agents: HeLa, COS-7, and COLO 316 
cells were seeded on 8-well chamber glass slide at 3.0 X104 cells per well in Dulbecco’s 
modified Eagle’s medium supplemented with FBS (10%) and incubated for 24 h at 37 
8C in a humidified atmosphere containing CO2 (5 %). Cells were then incubated with L-
15 medium (no FBS added) and placed on an inverted epifluorescence microscope 
(Model IX81, Olympus, Center Valley, PA) equipped with a heating stage maintained at 
378C. The microscope is conFig.d with a spinning disk unit to perform both confocal 
and wide-field fluorescence microscopy. Images were collected by using a Rolera-MGI 
Plus back-illuminated EMCCD camera (Qimaging, Surrey, BC, Canada). Images were 
acquired by using phase contrast and three standard fluorescence filter sets: CFP 
(lex=43620 nm/lem=48040 nm), Texas Red (lex=56040 nm/lem=63075 nm), and 
FITC (lex=482 35 nm/lem=53640 nm). Cells were cotreated with TAT or E3/E5- 
TAT (2 M) in L-15 medium containing fluorescent imaging agents (10 M) for the 
fluorescent proteins EGFP (enhanced green fluorescent protein), mCherry, and tdTomato 
(obtained as previously described). For the dextrans (10 and 70 kDa anionic dextran–
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fluorescein, 10 and 70 kDa neutral dextran– tetramethylrhodamine, and 70 kDa neutral 
Dextran–Texas Red) 250 M (for 10 kDa dextrans) or 36 M (70 kDa dextrans) of 
fluorescent imaging agent was used.[10] After incubation at 4 or 37? for 15 or 60 min, 
the cells were washed with PBS five times and the medium was replaced with fresh L-15. 
The integrity of the plasma membrane of the cells was determined by addition of the 
cell-impermeable DNA stain SYTOX Blue. Cells with a fluorescent blue nucleus, as 
detected with the CFP filter set, were considered compromised or dead. The cells that 
were not stained by SYTOX Blue were further confirmed to be alive by detection of 
active transport of intracellular endocytic vesicles. To inhibit cell surface binding of the 
delivery peptides, heparin sodium salt (1 mgmL-1) was added during the co-incubation 
step. To inhibit acidification of the endolysosomal organelles, cells were pretreated with 
bafilomycin (200 M) for 20 min. Cells were then co-incubated with the fluorescent 
macromolecules and the delivery peptides in L-15 supplemented with bafilomycin (200 
nM). The fluorescence intensities within cells were measured using the SlideBook 4.2 
software (Olympus, Center Valley, PA). The mean intensity within cells imaged with the 
FITC or Texas Red filters was measured as the total intensity of the cell divided by its 
area. The same protocol was used for cells with either punctate or diffuse distributions. 
Mean fluorescence intensities were measured over a population of 3000 cells and 
experiments were reproduced three times. 
 
3.4.4 Live cell assay for the delivery of PAD
Cells grown on 96-well plates were treated with  PAD (20 M) and TAT (5 M)  or
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E5-TAT (3, 5, or 7 M) in L-15. For the inhibition of macropinocytosis, cells were first 
pretreated with of amiloride (50 nM; Sigma) for 30 min, and then with the peptides 
while keeping amiloride present. After 1 h incubation, the cells were washed with fresh 
L-15 medium again and incubated at 37? for additional 3 h. The number of live cells 
present in each well was then determined by using the Vybrant MTT Cell Proliferation 
Assay Kit (Molecular Probes). After 1 h incubation the cells were washed with L-15. 
SYTOX Blue (5 M) was added and cells were incubated for 15 min at 37?. Cells were 
then placed on the microscope and images were acquired in the blue fluorescence 
channel for detection of SYTOX Blue and red fluorescence channel for detection of 
TMR. 
 
3.4.5 Characterization  of  the  binding  interactions  between  the  delivery peptides  
         and proteins 
The affinity of the delivery peptides TAT and E5-TAT for proteins was assessed by 
native gel electrophoresis. Three model protein systems were used in these experiments: 
mCherry, bovine serum albumin (BSA), fetal bovine serum (FBS). The latter were used 
because arginine-rich peptides have been shown to interact with FBS proteins. In 
particular, non-covalent binding of the positively charge peptide R12 (pI = 13, charge of 
+12 at pH 7) to the negatively charged BSA (pI = 4.7, charge of approximately -18 at pH 
7) could be detected.[4] Although BSA was not used in this delivery assays, this protein 
has a lower pI than mCherry (pI = 6.6) and therefore serves as a control to test whether 
TAT or E5-TAT might bind to negatively charged proteins. 
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The peptides TAT and E5-TAT were labeled with fluorescein (Fl) by coupling of 
this fluorescent molecule to the N-terminus of the peptides during SPPS assembly to 
generate Fl-TAT and Fl-E5-TAT. Fl-TAT and Fl-E5-TAT were incubated in L-15 
supplemented with BSA, mCherry, or with 10% FBS. The delivery peptides and protein 
samples were incubated for 30 minutes at 37°C to allow for binding and reproduce the 
conditions used for the cell-based microscopy assays (room temperature were also tested 
and yielded similar results). In order to have enough material for analysis, the 
concentrations used were however about 10 to 100-fold higher than those used for the 
imaging assays. The samples were then analyzed by native gel electrophoresis (15 L 
were loaded for each sample). The native 12% gels, and Tris/Glycine running buffers 
were prepared according to regular SDS-PAGE protocols but with the difference that 
SDS was replaced by glycerol and that the pH of the running buffer was adjusted to 8 (a 
pH at which the TAT lysine and arginine residues will remain protonated). 
Electrophoresis was ran at 150 mV for 2hr and the protein/peptide complexes were 
detected using a fluorescence scanner (Typhoon, GE healthcare) to obtain images of the 
fluorescence signals of fluorescein labeled peptides and of the fluorescent mCherry 
protein. The imaged gels were then stained with coomassie according to standard 
protocols. 
Fig. 3-2 and 3-3 show the results of these experiments. As shown in Fig. 3-7, Fl-
TAT was found to bind to serum proteins but this could only be detected when the 
peptide was incubated at 50 mM or more. In contrast, Fl-E5-TAT could not be detected 
to bind to the serum proteins under the conditions tested. To confirm that the peptide 
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was present in the sample loaded on the gel, the sample was centrifuged at 17 k rpm for 
10 min and the supernatant was analyzed by HPLC. This analysis confirmed that the 
peptide was present in the sample at the desired concentration. The binding interactions 
of the peptides to pure proteins were then characterized with BSA and mCherry as 
shown in Fig. 3-3. Smears of Fl-TAT, and to a lesser extent Fl-E5-TAT, could be 
detected when the peptides were incubated at high concentrations and in stoichiometric 
excess with BSA. These smears were of low intensity and could not be observed in the 
coomassie stained gel, indicating that the peptide/protein complexes that might generate 
these smears represent a small population of the total BSA species (e.g. there are no 
observable differences between the BSA control, Fig. 3-3 (a) lane 7, and the 
peptide/protein samples, lanes 2, 3, 5, and 6). For the samples incubated with mCherry, a 
very faint smear was detected for Fl-TAT/mCherry samples (Fig. 3-3 b, lanes 2 and 3) 
but no signal from Fl-E5-TAT was observable. mCherry labeled with fluorescein 
(mCherry-Fluorescein, Fig. 3-3 b, lane 7) was used as a control to validate that both 
mCherry and fluorescein fluorescence could be detected (the protein was prepared as 
previously reported, the stoichiometry of mCherry:fluorescein is 1:1).[1] The amount of 
mCherry-Fluorescein loaded (15 L of 20 M of protein loaded) on the gel was the same 
as the amount of mCherry loaded in lanes 2, 3, 5, and 6 from the mCherry/peptide 
incubation samples. I therefore reasoned that the green fluorescence obtained from lane 
7 could be used as an internal calibration to assess the overall amount of peptide bound 
to mCherry in lanes 2, 3, 5, and 6 (e.g. a 1:1 Fl-peptide/mCherry complex should give a 
similar signal as mCherry-Fluorescein in the green fluorescence channel). The white 
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area in the center of Lane 7 represents a fluorescence signal that has saturated ( > 
100,000 counts) the detector. High sensitivity for the detector was however required to 
detect the signals of lanes 2 and 3 (signal of < 1000 counts; when lane 7 is not saturated, 
the signals of lanes 2 and 3 cannot be detected). The total fluorescence intensities of lane 
3 and 7 were integrated over the whole lane area using the ImageQuant Software 
(Molecular Dynamics) and compared (each saturated pixels in lane 7 were counted to 
have the maximal signal of 100,000 counts even though the “real” signal is probably 
much greater). I found that the green fluorescence present in lane 3 was less than 0.2 % 
of the signal of lane 7. 
Overall, these results indicate that although TAT or E5-TAT might bind to 
negatively charged proteins such as BSA, the population of TAT/BSA or E5-TAT/BSA 
complexes formed appears to be of very low concentration. With mCherry, one of the 
fluorescent proteins tested in the delivery assays, no E5-TAT/mCherry complexes could 
be detected at all while a small amount of TAT/mCherry complexes was. It is important 
to note that the peptide concentrations and peptide to protein ratios used were far greater 
than those used for the peptide/protein co-incubation microscopy assays (e.g. 2 M 
peptide + 10 M protein for delivery assays versus 40 M peptide + 20 M protein for 
the binding assays). Accordingly, it is expected that absence of binding interactions in 
the binding assays is likely to indicate that no binding interactions take place in the 
samples used for the delivery assays. It should be noted that fluorescein might affect the 
protein binding behavior of the peptides. However, given that it is a hydrophobic 
molecule, one might expect that fluorescein would enhance the hydrophobic interactions 
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between the peptides and the tested proteins rather than diminish them. In addition, 
fluorescein has one negative charge at pH 7 that could interfere with the positively 
charged TAT. However, E5-TAT should be affected in a similar manner. Overall, I 
conclude that E5-TAT does not bind to mCherry at detectable levels while TAT exhibits 
low level of unspecific binding. It is then surprising and interesting to note that E5-TAT, 
despite containing the TAT sequence and an additional hydrophobic region, appears to 
have less binding affinity for proteins than TAT itself. My preliminary data suggest that 
E5 and TAT might interact with one another. This interaction could then reduce the 
interactions with other binding partners. This model will be the object of future studies. 
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4. MODELING OF ENDOSOMOLYTIC ACTIVITY OF HA2-TAT PEPTIDES 
WITH RED BLOOD CELLS AND GHOSTS* 
4.1 Introduction 
E5-TAT can enhance the endosomal release of endocytosed macromolecules. This 
process remains, however, obscure. In sections 2 and 3, it has been demonstrated that the 
inhibitor of endosomal acidification inhibits E5-mediated endosomal escape. After cells 
were pretreated with bafilomycin, the efficiency of protein delivery by E5-TAT 
significantly decreased. However, due to the complexity of the cellular environment and 
the small size of endosomes, it is too difficult to observe how E5-TAT mediates 
endosomal membrane disruption directly in live cells. In addition, there are many 
different processes contributing to the observed results that take place simultaneously 
within live cells and these cannot be eliminated. Therefore, a simpler but similar system 
compared to cellular environments needs to be applied instead.  
Since the plasma membrane of erythrocytes (Red Blood Cells, RBCs) has similar 
composition to common mammalian lipid membrane and because erythrocytes are 
relatively stable in acidic environments, they can function as a structural model for 
endosomal membrane (89,90). To further investigate the membrane disruption 
mechanism of E5-TAT, the pH-dependent lysis activity of HA2-TAT peptides are first 
tested in vitro with erythrocytes by hemolysis assay.  
______________  
*Part of this section is reprinted with permission from Modeling of the endosomolytic 
activity of HA2-TAT peptides with red blood cells and ghosts by Lee YJ, Johnson G, Pellois JP 
Biochemistry. 2010 Sep 14;49(36):7854-66, Copyright© 2010 by American Chemical Society. 
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4.2 Results 
4.2.1 Peptide design
Several HA2-TAT analogues were synthesized by solid-phase peptide synthesis 
(SPPS). HA2 analogues were considered in this study: E3, E5 (Table 4-1). E3 consists of 
the wild-type HA2 sequence (residues 1-23, strain X31) modified with the mutations 
M17L and D19E in order to avoid methionine oxidation and aspartyl isomerization 
during synthesis. E3 contains the residues Trp-21 and Tyr-22 because these residues 
appear to increase the hemolysis activity of HA2 peptides (70). E5 differs from E3 by 
including the G4E and G8E mutations. Addition of these two glutamate residues has 
been demonstrated to increase the lysis activity of HA2 analogues (55,63,66,70). TAT 
was placed at the C-terminus of the HA2 analogues so as not to affect the insertion of the 
HA2 peptides into membranes (55,64). For fluorescence labeling, fluorescein 
isothiocyanate (Fl) was introduced at the N- or C-terminus of E5-TAT during solid 
phase assembly to generate Fl-E5-TAT or E5-TAT-Fl, respectively. Fl-E5-TATwas 
synthesized after E5-TAT-Fl was found to be poorly soluble. Modifications at the N-
terminus of HA2 have however been found to reduce the fusion and hemolytic activities 
of HA2 analogues because it is the N-terminus of HA2 that inserts into lipid bilayers 
(55,64). Therefore, in order to minimize the effect that the fluorophore might have on the 
peptide’s activity, the flexible linker 6-aminohexanoic acid (Ahx) was incorporated 
during synthesis between Fl and the N-terminal glycine. Fl-E5-TAT was found to 
closely mimic the hemolytic activity of E5-TAT (Fig. 4-1B, C on page 81). Fl-E5-TAT 
was  therefore  preferred as  the  fluorescent analogue  of  E5-TAT used  to  visualize the  
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Table 4-1 Sequences of the HA2-TAT peptides investigated 
Name Amino Acid Sequence  
HIV TAT (48-57) GRKKR RQRRR 
Influenza HA2 (1-23) GLFGA IAGFI ENGWE GMIDG WYG 
E3-TATa GLFGA IAGFI ENGWE GLIEG WYGGR KKRRQ RRR 
E5-TATa GLFEA IAEFI ENGWE GLIEG WYGGR KKRRQ RRR 
Fl-E5-TATb Fl-Ahx-GLFEA IAEFI ENGWE GLIEG WYGGR KKRRQ RRRK 
E5-TAT-Fl GLFEA IAEFI ENGWE GLIEG WYGGR KKRRQ RRRK(Fl) 
E5(3,7)-TAT GLEGA IEGFI ENGWE GLIEG WYGGR KKRRQ RRR 
E5-R9 GLFEA IAEFI ENGWE GLIEG WYGGR RRRRR RRR 
a the underlined sequence represents the HA2 peptide obtained after trypsin digest. 
b Ahx is the linker 6-aminohexanoic acid. 
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peptide interacting with cellular membranes.  
Numerous studies with the HA2 fusion peptide have shown that this amphiphilic 
peptide behaves poorly in water, making the biochemical study of its properties difficult. 
Han and Tamm have reported the design of host-guest systems where lysine-rich 
unstructured C-terminal sequences could solubilize N-terminal HA2 guest sequences (5). 
Therefore it is reasoned that the highly charged TAT peptide could promote the same 
effect. The solubility of the peptides E3-TAT and E5-TAT in aqueous buffers was first 
assessed by monitoring the extent to which the peptides remain in solution for extended 
periods of time. The peptides were dissolved in PBS to 5 M, and the samples were 
centrifuged at high speed every hour to separate the soluble peptides from possible 
precipitate. The concentration of the peptides remaining in solution was then determined 
by HPLC analysis. Under these conditions, all peptides appeared to remain in solution 
for at least 24 h. To determine the effect that TAT might have on the solubility of the 
amphiphilic HA2 sequences, the control peptides TAT, E3, and E5 were also 
synthesized by SPPS. TAT was obtained in high yield, but this approach did not yield 
satisfactory results for E3 and E5 as the peptides precipitated and degraded after HPLC 
purification and storage (65). Instead, E3 and E5 were obtained by trypsin-mediated 
cleavage of the TAT peptide from E3-TAT and E5-TAT. HPLC and mass spectrometry 
analysis confirmed that single E3 or E5 products with a C-terminal arginine were 
produced with less than 3% of the uncleaved peptide remaining. Using this approach, the 
peptide was found to be soluble and stable in PBS for at least 1 h at room temperature. 
However, like the synthesized peptides, the E3 and E5 peptides produced by TAT 
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cleavage also showed a tendency to precipitate and degrade over time as determined by 
HPLC and mass spectrometry. Overall, these results suggest that the highly charged and 
hydrophilic TAT sequence has a solubilizing and stabilizing effect on the amphiphilic 
E3 and E5 sequences. 
 
4.2.2 HA2-TAT peptides lyse erythrocytes in a pH-dependent manner                                                    
      The pH-dependent hemolysis activities of the HA2-TAT peptides were characterized 
by an in vitro erythrocyte lysis assay. The peptides were incubated with human RBCs in 
PBS with the pH adjusted to different values. The release of hemoglobin from lysed cells 
was then measured spectrophotometrically at 450 nm 30 min after incubation was 
initiated (hemolysis is complete at this time point in all of the assays). E3-TAT, E5-TAT, 
E3, and E5 all show a clear pH-dependent lysis activity and display sigmoidal response 
curves consistent with a single protonation model (Fig. 4-1A). E3-TAT, E3, and E5 
displayed an identical apparent pK50 of approximately 5.8 (pH at which 50% of 
maximum hemolysis is obtained). This pK50 is consistent with values reported for HA2 
peptides and the X-31 virus itself (64,91). In contrast, the hemolysis response curve of 
E5-TAT is significantly shifted toward higher pH and displays an apparent pK50 of 6.7. 
E5-TAT also appears to have a higher activity than E3-TATat all pHs (Fig. 4-1A).The 
activities of E3 and E5 were much reduced in comparison to E3-TAT and E5-TAT. E3 
and E5 required a concentration of approximately 4 or 3 M to display a hemolysis 
activity at pH4.5 similar to that of E3-TAT and E5-TAT at 1.5 M. A precise 
comparison of the activity  of  the E3/5-TAT  and  E3/5 peptides  was  however rendered 
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Figure 4-1 (A) Hemolysis activities ofHA2 and HA2-TAT analogues as a function of 
pH. Hemolysis is reported as a percentage of the maximal release of hemoglobin 
obtained by treatment of the red blood cells with the detergent Triton X. TAT shows no 
lysis activity while E3, E5, E3-TAT, and E5-TAT display sigmoidal response curves. E3, 
E5, and E3-TAT have a similar pK50 of approximately 5.7. In contrast, E5-TAT 
displays apK50 of 6.7. E3 and E5 are overall less active than E3-TAT or E5-TAT as 
they require higher concentrations to achieve similar hemolysis percentages at pH4.5. 
The plot fitting was performed as described in the Experimental Procedures. The data 
represent the average of at least three experiments. The standard deviation for each data 
point, not represented for clarity, was 5%hemolysis or less. Note that the concentration 
of E3 and E5 reported might be overestimated as the peptides might aggregate and 
precipitate during the experiment. These data might therefore not accurately reflect the 
hemolytic activity of the peptide precisely, but, on the other hand, serve to establish the 
differences in pK50 between the HA2 peptides and their HA2-TAT analogues. (B, C) 
Comparison of the hemolytic activities of E5-TAT and Fl-E5-TAT.While Fl-E5-TAT 
has a lower HD50 than E5-TAT, both peptides have an identical pK50. (D) Hemolytic 
activities of Fl-E5-TAT at pH7.0 (diamonds) and 4.0 (triangles) as a function of peptide 
concentration and for 1.25% RBC suspensions. The data fit the equations y=27.2x at 
pH7 and y=4.9x at pH 4.0 with R2 of 0.90 and 0.98, respectively. The HD50 of the 
peptide are 1.8 and 10.2 M at pH 4.0 and 7.0, respectively. 
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difficult because of the poor solubility of E3/5. Finally, TAT did not induce erythrocyte 
lysis at any of the concentrations (up to 80 M) or pH values (4.5-7.5) tested. Together, 
these results indicate that the increase in activity and the change in pH response 
observed for E5-TAT appear to be dependent on the presence of both TAT and the G4E 
and G8E mutations since neither E5 nor E3-TAT displays the same characteristics. 
      The effect of the concentration of peptide used during the hemolysis was evaluated 
for E5-TAT and Fl-E5-TAT. The results obtained with the fluorescently labeled peptide 
are shown in Fig. 4-1D. The HD50 (hemolytic dose for 50% lysis) of E5- TAT and Fl-
E5-TAT were approximately 2.6 and 10.2 M at pH 7.0, respectively, and 0.5 and 1.8 
M at pH4.0, respectively. In both cases, the hemolytic activity of the peptide is 
increased approximately 5-fold when the pH is decreased from 7.0 to 4.0. Despite an 
overall decrease in the activity of Fl-E5-TAT as compared to E5-TAT, the pK50 of both 
peptides were identical at 6.7 (Fig. 4-1C). Overall, these data suggest that Fl-E5-TAT is 
a fluorescent analogue of E5-TAT that can closely reproduce its properties. 
 
4.2.3 Fl-E5-TAT interacts with RBC in a pH-dependent manner 
      The hemolytic activity and binding of Fl-E5-TAT to RBCs were investigated by 
microscopy. The lysis of RBCs after peptide addition was detected by the decrease in the 
cells’ optical contrast observed by bright field microscopy and as reported by Jay and 
Rowlands (6). The products of the lysis were ghost cells with a visible membrane but 
with an interior invisible upon bright field imaging. This is consistent with cells losing 
their content as lysis proceeds and with the lumen of the ghost being filled with the 
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surrounding media. Lysis was also confirmed by monitoring the loss of red 
autofluorescence of RBCs upon ghost formation. It is important to note that the red 
fluorescence present inside the RBCs cannot be accounted by hemoglobin as 
hemoglobin has been clearly shown to be poorly fluorescent. Instead, porphyrins and 
other metabolites are more likely to be the fluorescent material observed in these 
experiments (92). Yet, loss of autofluorescence further confirms that the lysed RBCs are 
losing their content. In my hands, loss in optical contrast in bright field imaging and loss 
of red autofluorescence were simultaneous. 
       Red blood cells were incubated with Fl-E5-TAT at pH 4.5 or 7.0, and the binding of 
the peptide to membranes was monitored by fluorescence microscopy (Fig. 4-2). Fl-E5-
TAT was first incubated with RBCs at pH 7.0 and at a concentration below its HD50 (5 
M, HD50 = 10.2 M) so as to prevent extensive lysis. The fluorescence of Fl-E5-TAT 
appeared to be diffused in solution, and no association of the peptide to the membrane of 
RBCs could be observed. In contrast, when incubated at pH 6.0, 5.0, or 4.5, the peptide 
was found to increasingly accumulate at the surface of intact RBCs (Fig. 4-2 and Fig. 4-
3; a concentration of 1 M peptide was used to minimize lysis). Together, these results 
suggest that Fl-E5-TAT remains predominantly soluble at pH 7.0 but associates with the 
membrane as the pH decreases. 
      Addition of the E5-TATor Fl-E5-TAT to RBCs incubated at pH 4.5 at concentrations 
above their HD50  (5 M) induced  rapid lysis.  Prior to lysis, RBCs appeared as a mixed  
population of  concave and spherical  cells. The presence of spherical cells is  consistent  
with the swelling observed when concave cells are exposed to stress such as low pH (93). 
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Figure 4-2 Binding of Fl-E5-TAT to RBCs and ghosts as a function of pH. RBCs were 
incubated with 1 or 5 M Fl-E5-TAT at pH 7.0 or 4.5, and the samples were observed by 
fluorescence (Fl-E5-TAT, FITC image, pseudocolored green) and bright field 
(RBCs/ghosts) microscopy. At pH 7.0 and at a low concentration of peptide (5 M, 
below the HD50 at pH 7.0), the RBCs are intact, and the peptide appears to be 
homogeneously distributed in solution. No binding to the surface of the RBCs is 
detected under these conditions. At pH 4.5 and at 1 M peptide (below the HD50 at this 
pH), the RBCs remain intact, but the peptide appears to preferentially partition at the 
membrane of the cells. At pH 4.5 and 5 M peptide (above the HD50 at this pH), the 
RBCs are lysed, and the peptide binds to the membrane of the ghosts formed. 
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Figure 4-3 A) Binding of Fl-E5-TAT (1.0 M) to intact RBCs as a function of pH as 
observed by fluorescence microscopy. The peptide was added to 1.25% RBC 
suspensions and the samples were imaged after 5 minutes of incubation. At pH 7.0, the 
fluorescence signal is detected in solution. As the pH is reduced, the peptide accumulates 
at the membrane as detected by an increase in the contrast between the signal at the 
membrane and the signal in solution (the methods used are the same as in Fig. 4-2). Note: 
The samples also contain 5 to 10% of lysed ghosts but intact RBCs can easily be 
identified in the bright field image because of their darker contrast. B) The samples 
described in A) were centrifuged to separate RBC-bound peptides from the fraction of 
peptide remaining in solution. The amount of soluble peptide was determined by SDS-
PAGE and densitometric analysis. Each sample was normalized to a pH 7.0 control 
containing the fluorescent peptide but no RBCs (= 100% peptide in solution). The data 
represent the average of three experiments and the error bars correspond to the standard 
deviation. Binding Assay. The binding of Fl-E5-TAT to intact RBCs as a function of pH 
was determined by incubating peptide (1 M, <HD50 to minimize lysis) with 1.25% 
RBC suspensions in PBS at different pH values (adjusted with HCl or NaOH, 
4.5<pH<7.5). After 5 min incubation, the samples were centrifuged for 5 minutes at 
1500g. The amount of peptide present in the supernatants was analyzed by SDS-PAGE 
using 12% SDS-gel (pH 8.8). The gels were imaged with the Typhoon 9410 imager (GE 
Healthcare) set with an excitation wavelength of 488 nm and a green emission filter at 
526 nm to detect the fluorescence of Fl-E5-TAT. Densitometric analysis of the intensity 
of the Fl- E5-TAT bands was performed with the ImageQuant 5.0 software. The 
fluorescence of the fluorescein label on E5-TAT is pH dependent. However, because all 
samples are exposed to the same pH within the gel, the fluorescence intensity of the 
bands is only proportional to the amount of peptide present in the sample. The data were 
normalized using a sample containing Fl-E5-TAT at pH 7.0 but with no RBC present as 
the one hundred percent soluble control. 
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      Lysis of cells that were initially spherical did not appear to induce an observable 
change in the diameter or morphology of the cell (Fig. 4-4). Initiation of lysis after E5-
TAT addition was different from cell to cell, but once initiated, lysis was complete in 90 
(30 s on average to reach completion (average and standard deviation obtained from a 
population of 50 cells) (Fig. 4-4). Similar results were obtained for E5-TAT and Fl-E5-
TAT. In the case of Fl-E5-TAT however, binding of the fluorescent peptide to the 
surface of ghosts was clearly observable by fluorescence microscopy (Fig. 4-2). RBCs 
that were not lysed by the end of the experiments typically showed little fluorescence 
and peptide binding on their surface. 
 
4.2.4 Fl-E5-TAT  permeabilizes  membranes   in   a   manner   not   reversed   under
         different pH values 
       Next, I tested whether the ghost obtained by E5-TAT-mediated hemolysis remained 
permeable after hemolysis and whether permeability could be reversed. Ghosts were 
obtained by treatment of RBCs with E5-TAT at pH 4.5. The ghosts were then either kept 
in the pH4.5 media with the E5-TAT peptide present or washed with fresh pH 4.5 or 7 
PBS buffer at 37 C. These latter steps consisted of a repeated dilution protocol as ghosts 
could not be washed under stringent conditions without loss of membrane integrity and 
membrane collapse. A 10 kDa dextran-fluorescein was then added to the RBCs and 
ghosts, and the samples were then observed by fluorescence microscopy. Intact RBCs 
had internal fluorescence signals much lower than the fluorescence of the surrounding 
solution (Fig. 4-5). This is consistent with  the dextran not being  able to penetrate RBCs. 
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Figure 4-4 Time course of lysis and ghost formation from single RBCs determined by 
fluorescence and bright field microscopy. RBCs were incubated in PBS at pH 4.5 and 
imaged every 10 s in a time-lapse experiment. After 50 s, the cells were treated with 1 
M E5-TAT, and imaging was immediately resumed. Lysis was assessed by measuring 
the decrease in optical contrast of cells in the bright field image (data displayed) or the 
decrease in their autofluorescence in the red fluorescence image (not represented but 
identical results were obtained using this method). Cell leakage appears to be initiated at 
slightly different times. Once initiated, lysis consistently took on average 90 (30 s to 
reach completion (n=50 cells, four represented in the Fig.). Bright field and fluorescence 
overlay images (cell autofluorescence, pseudocolored red) show that the morphology of 
the cells does not change during the experiment and that their diameter remains 
approximately constant.   
 
 
89 
 
      In contrast, ghosts showed an internal fluorescence equal to that of the media. This 
indicates that the 10 kDa dextran-fluorescein had freely penetrated into the ghosts and 
that the ghosts remained permeable to macromolecules (Fig. 4-5). Fluorescence imaging 
was also performed immediately after diluting the media of the sample. As seen in Fig. 
4-5, fluorescent ghosts were clearly observed over a darker background, further 
confirming that the fluorescent dextran had penetrated the ghost. Similar experiments 
were reproduced with Fl-E5-TAT. This time, fluorescence imaging revealed that the Fl-
E5-TAT peptide was still bound to the membrane even after repeated dilutions and 
washing steps at either pH 4.5 or pH 7 (Fig. 4-5). Together, these results suggest that the 
peptide remains stably anchored to the ghost membrane at either low or neutral pH and 
that this results in the formation of ghosts that are not resealed. 
 
4.2.5 Peptide binding to RBC is dependent on membrane composition 
 During the course of the experiments, I observed that the fluorescence at the 
membrane of ghosts increased during lysis and occasionally after lysis had taken place. 
This suggested that binding of the peptide might not be dependent on pH only but on 
changes in membrane composition that might occur during lysis. To address this issue, I 
first tested whether the TAT sequence might be involved in this effect. TAT labeled with 
fluorescein, Fl-TAT, was added to RBCs at either pH 4 or pH 7. In both cases, no 
staining of the RBCs’ membranes and no lysis could be observed. However, addition of      
Triton X and lysis led to an immediate increase in membrane staining at both pHs (Fig. 
4-6) .  Binding of  Fl-TAT to  the  membrane of  the  ghosts  formed  by  treatment   with   
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          A)                                                                        B) 
Figure 4-5 Ghosts remain permeable after lysis and Fl-E5-TAT remains tightly bound to 
their membranes. (A) Binding ofFl-E5-TATto ghosts is maintained after washing at pH 
7. Ghosts were formed by treating RBCs with 3 MFl-E5-TAT at pH 4.5. The ghosts 
were then washed with PBS at pH7.0 and imaged by fluorescence microscopy. Staining 
of the ghosts by the peptide was not reduced by repeating the washes or with time. 
Similar results were obtained when the pH of the PBS was 4.5. (B) The fluorescent 
marker 10 kDa dextran-FITC was added to cells lysed by treatment with E5-TAT (3 M) 
at pH 4.5. A clear fluorescence contrast is observed between the exterior and interior of 
intact RBCs. Conversely, ghosts display a fluorescence signal similar to that of the 
media surrounding them, suggesting that the fluorescent dextran is able to penetrate 
ghosts but not intact RBCs. Rapid dilution of the media generates a higher fluorescence 
contrast inside ghosts, confirming that the dextran is present in the lumen of ghosts.  
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Figure 4-6 (A) Binding of Fl-TAT to RBCs and ghosts. Fl-TAT (5 M) was added 
to1%RBCs, and the cells were observed by phase contrast and fluorescence microscopy. 
Fl-TAT appears to be diffusely distributed in solution and no accumulation of the 
peptide on the membrane of RBCs can be detected under these conditions. Addition of 
0.1% Triton X results in rapid lysis of the RBCs. Fl-TAT is then observed to bind to the 
membrane of the formed ghosts. The set of images after addition of TritonX represents 
the same field of cells represented before addition and was acquired less than 10 s after 
addition of the detergent. Fl-TAT also binds to ghost obtained by E5-TAT-mediated 
hemolysis. RBCs were treated with 1 ME5-TAT at pH4.5, and Fl-TAT (5 M) was 
added to the sample. While binding of Fl-TAT to the membrane of ghosts is clearly 
visible, the fraction of peptide that remains in solution appears much larger than in the 
Triton X experiment. The data represented were obtained at pH 4.5, but similar results 
were obtained at pH7. (B) AnnexinV binds to ghosts but not to intact RBCs. Cells were 
exposed to 1 mM E5-TAT at pH 6 to generate a mixture of intact RBCs and ghosts. The 
sample was treated with FITC-annexin V, and binding of annexin V to membranes was 
detected by fluorescence microscopy (FITC image, pseudocolored green). 
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E5-TAT at pH 4.5 could also be observed. However, the contrast between the signal in 
solution and the signal at the membrane was much reduced in this experiment, 
suggesting that E5-TAT and TAT are competing for binding. Together, this indicates 
that TAT binds to lysed cells and that TAT has access only after lysis to membrane 
components that are not accessible before lysis. In particular, I reasoned that these 
observations could be the result of the binding of TAT to negatively charged 
phospholipids. Interestingly, phospholipid phosphatidylserine (PS) is known to be 
predominantly present at the inner leaflet of the membranes of intact erythrocytes 
(94,95). TAT has also been reported to bind liposomes containing anionic phospholipids 
(4,96). TAT and E5-TAT could therefore bind to PS after E5-TAT-mediated hemolysis. 
PS could for instance flop through the aqueous pores formed during lysis and become 
exposed on the surface of the cells. Alternatively, E5-TAT could have access to luminal 
PS after lysis and diffusion into the permeable ghost. In order to test whether PS might 
be involved in the observed E5-TAT and TAT binding to ghost cells, FITC-annexin V, a 
fluorescently labeled protein with an extremely high affinity for PS, was added to ghosts 
obtained by E5-TAT-mediated hemolysis (41). As shown in Fig. 4-6B, labeling of the 
membrane of ghosts by annexin V could be clearly observed while no labeling was 
observed for intact RBCs. 
 
4.2.6 Heparin inhibits membrane binding of E5-TAT and hemolysis       
       Other negatively charged molecules that TAT might interact with are the 
glycosaminoglycans present on the surface of mammalian cells. In particular, TAT binds
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to cell-surface heparan sulfate (HS) proteoglycans, and this interaction appears to play a 
key role in the translocation of the peptide inside cells. Degradation fragments of HS are 
present within endocytic compartments, and these molecules have been proposed to 
inhibit the interaction of TAT with endosomal lipid bilayers and thereby reduce the 
efficiency with which the peptide can escape from endosomes (see Discussion). I was 
therefore interested in determining whether binding of E5-TAT to HS degradation 
fragments would inhibit the lytic activity of the peptide. To test this hypothesis, RBCs 
incubated with the HS analogue heparin were used to model the lumen of endosomes 
that would contain soluble HS degradation fragments. E5-TAT was added to samples of 
heparin/RBCs, and the extent of hemolysis was measured spectrophotometrically. E5-
TAT-mediated hemolysis at pH4.5 was greatly reduced when RBCs were incubated with 
heparin (Fig. 4-7A). The extent of this inhibition was dependent on the concentration of 
heparin used, and hemolysis could be almost completely abolished when a large excess 
of heparin was used (10 mg/mL). On the other hand, the hemolysis activity of E5 was 
not affected by addition of heparin at any of the concentrations tested (1-10 mg/mL). In 
addition, binding of Fl-E5-TAT to the surface of RBCs at pH 4.5 was greatly reduced 
when heparin was added to the media (Fig. 4-7B). Together, these results suggest that 
heparin inhibits the binding of the peptide to the membrane of RBCs. As a consequence, 
the peptide is then unable to cause hemolysis. 
4.3 Discussion 
       The delivery peptides investigated  in this study are chimeric peptides  derived  from  
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Figure 4-7 (A) Heparin inhibits the hemolytic activity of E5-TAT but not that of E5. 
RBCs were treated with 3 ME5-TATorE5at pH4.5 in the absence or presence of 
heparin (1mg/mL). (B) Heparin inhibits the binding of Fl-E5-TAT to the membrane of 
RBCs. RBCs were treated with 1 MFl-E5-TAT at pH 4.5 in the absence or presence of 
heparin (1 mg/mL). No binding of the peptide to the membrane is observable when 
heparin is present in the sample and hemolysis is inhibited (RBCs in the image are 
intact). 
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HA2 fusion peptide of influenza hemagglutinin protein and the TAT peptide derived  
from the HIV transactivator of transcription protein (residues 47-60). These HA2-TAT 
peptides are designed to combine the endocytosis-inducing activity of TAT and the pH-
dependent endosomal release activity of HA2. The results however highlight a complex 
interplay between the two peptides and several important parameters that affect their 
lytic activities. The first evidence of how TAT might affect the activity of HA2 peptides 
is given by the increase in hemolysis activity measured between E3/E5-TAT and E3/E5. 
It is well established that HA2 peptides are poorly soluble. Addition of the hydrophilic 
TAT sequence could therefore reduce the aggregation propensity of the HA2 peptides 
and be the cause of the increase in activity observed (97). Tamm and coworkers have 
indeed reported that addition of lysine residues to the C-terminus of HA2 sequences 
could greatly increase the solubility of the peptides (5). Consistent with this idea is the 
observation that E3 or E5 would rapidly aggregate and degrade during the experiments 
while E3/E5-TAT would not. The effect of TAT on the activity of E5 was however more 
pronounced than on the activity of E3. In particular, a dramatic shift in the hemolysis 
pK50 could be observed, and this effect appeared dependent on the presence of both 
TAT and the G4E and G8E mutations. This suggests the presence of electrostatic 
interactions between the positively charged residues of TAT and the glutamate residues 
of E5. Tsien and co-workers have indeed reported that the addition of polyglutamate 
sequences to arginine-rich cell-penetrating peptides results in intramolecular electrostatic 
interactions that block the cell-penetrating activity of the peptides (98). In section 3, I 
have reported that E5-TAT, despite containing TAT, binds to a lesser extent than TAT to 
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a negatively charged protein such as BSA. This suggests that the TAT sequence in E5-
TAT has a reduced affinity for negatively charged molecules because it might be 
involved in intramolecular interactions with E5. Yet, one would expect that these 
interactions would stabilize E5 in its deprotonated form and lead to a decrease in the pK 
as of the glutamate residues and in hemolysis pK50. This is however contrary to my 
observations. Another possibility to explain for the observed increase in pK50 then 
might be that TAT increases the affinity of E5 for the lipid bilayer. HA2 peptides form 
amphipathic helices in membrane environments and upon protonation of their glutamate 
residues (56,99). The helices adopt a boomerang or hairpin-shaped structure at the 
lipid/water interface with hydrophobic residues facing the lipid environment. Based on 
these structures, the five Glu residues of E5 are expected to be located in close proximity 
on the interface exposed to water. Binding of E5-TAT to the membrane could therefore 
promote helix formation, leading to a clustering of the glutamate residues and to 
unfavorable like-charge repulsion between these residues. This would in turn facilitate 
the protonation of the Glu residues to avoid unfavorable Coulombic interactions and lead 
to an elevation of their pKa and of the pK50 observed (100). 
       To understand how E5-TAT disrupts membranes, the mechanism by which 
hemolysis is achieved was further explored. Like other HA2 peptides described, E5-TAT 
and Fl-E5-TAT exist in equilibrium between soluble and membrane-bound states (62). 
As observed by microscopy, a decrease in pH, and presumably protonation of the 
peptide glutamate residues, shifts this equilibrium to the membrane-bound state as the 
solubility of the peptide is reduced. Similar pH-dependent membrane partitioning has 
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been observed for AcE4K, an HA2 analogue similar to the E5 and Fl-E5 sequences used 
in this study (62). The hemolysis data are consistent with a single protonation model 
where the peptides undergo a transition from a soluble and nonlytic state A- to a 
membrane-bound and lytic state HA. The pK50 obtained from the hemolysis plot can 
then be interpreted as an acid dissociation constant for the A-/HA pair. In addition, the 
HD50 obtained at pH 4 and 7 represent the same total concentration of HA if one 
considers the Henderson-Hasselbach equation of the form pH = pK50 + log [A-]/[HA]. 
Lysis would therefore appear to only depend on the total amount of HA present in the 
membrane of RBCs. It is however important to note that the HD50 values correspond to 
peptide concentrations at which 50% of the RBCs are totally lysed and 50% are intact as 
opposed to 100% of cells 50% lysed. It therefore appears that the amount of peptide 
bound to the membrane of single cells has to reach a certain threshold before lysis can be 
initiated. 
       When lysis was carried out at concentrations well above the HD50 of the E5-TAT 
and Fl-E5-TAT, the membrane of ghosts collapsed and fused to one another. In contrast, 
lysis at concentrations at or below the determined HD50 did not appear to dramatically 
change the morphology of the membrane, and the diameter of ghosts remained 
approximately constant under these conditions. Leakage from single cells incubated with 
E5-TAT was initiated at different times, reflecting the fact that cells are heterogeneous 
and might have varying degrees of membrane fragilities. Once initiated, lysis was slow 
since 90 s was required on average to achieve complete hemolysis. Together, these 
results do not support the formation of dramatic lesions in the membrane as sometimes 
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observed with the hypotonic lysis of RBCs (101). Instead, they suggest that cell 
permeability is induced by the formation of aqueous pores large enough for the passage 
of hemoglobin or dextrans. The relatively slow leakage observed is also indicative of 
formation of a limited number of pores with a relatively small diameter rather than very 
large holes. Indeed, hemolysis by osmotic shock in hypotonic media was observed to be 
complete in 4 s for single RBCs (93,102). Considering that the diffusion constant of 
hemoglobin is approximately 7x10-7 cm2/s, it was then estimated that hemolysis could be 
achieved at the observed rate if cells contained 100 pores of a diameter of 70 Å 
(tetrameric hemoglobin has a spheroidal shape 65 x 55 x 50 Å ) (102). While such 
estimates are more qualitative than quantitative since the diameter of pores cannot be 
accurately determined similar calculations would indicate that E5-TAT mediates the 
formation of less than three equivalent pores per cell. 
       Ghosts obtained by hypotonic osmotic shock typically reseal within seconds in 
isotonic media and at 37 (102). In contrast, the ghosts obtained by Fl-E5-TAT-
mediated lysis remained permeable to dextrans under similar conditions. Interestingly, 
Fl-E5-TATcould not be washed from the membrane at either pH 4 or pH7.This is very 
different from what has been observed with AcE4K (62). A possible explanation for this 
observation is that TAT might play a role in the stable peptide binding to the membrane. 
Indeed, the data suggest that, while binding of E5- TAT to intact RBCs or liposomes is 
dependent on the E5 moiety, the binding of the peptide to ghosts is in part due to the 
affinity of TAT for the lysed membrane. Fl-TAT did not show significant binding to 
intact RBCs but was bound to the membrane of ghosts lysed with the detergent Triton X 
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or with E5-TAT. The possible explanation for these observations is that, upon lysis, the 
peptide is able to access molecules that are not available for binding in intact cells. A 
possible binding partner is PS, a negatively charged phospholipid which is located on the 
inner leaflet of the membrane of RBCs (95). My data do not rule out that the peptide 
binds to other molecules than PS upon lysis but demonstrate that binding to anionic 
phospholipids such as PS could account for the effects observed.  
      Overall, the binding of TAT to the lysed membrane of ghosts might contribute to the 
stable association of the peptide E5-TAT to the lipid bilayer and might explain in part 
why the peptide could not be washed away and why the permeability could not be 
reversed. In addition, it raises the possibility that TAT might play an active role in the 
lysis event. The E5 moiety in E5-TAT is clearly required to trigger lysis since TAT does 
not cause hemolysis on its own. E5 might be sufficient to initiate the formation of 
aqueous pores, and TAT might not contribute to this process at first. PS might then 
diffuse laterally through these pores as outer and inner leaflets are now connected to one 
another. One can therefore envision how the exposed PS would then lead to more 
peptide being recruited to this area because of the strong interaction between TAT and 
PS. This in turn might lead to more membrane disruption and could contribute to the 
increased activity and pK50 shift observed for E5-TAT when compared to E5. 
        HA2-TAT analogues can deliver macromolecules into the cytosolic space of 
mammalian cells. In particular, it has been shown in section 3 that E5-TAT can cause the 
release of macromolecules trapped inside endocytic organelles, and this activity is 
dependent on the acidification of these organelles. However, the delivery efficiency 
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associated with this peptide remains modest. Improving the properties of this delivery 
agent requires that one understand how this peptide functions. Yet, it is difficult to 
characterize the lytic activity of E5- TAT inside endocytic organelles because they 
represent a chemically complex and dynamic environment. After internalization at the 
plasma membrane, endocytic vesicles loaded with E5-TAT might undergo multiple steps 
of maturation, and the peptide might partition into various endocytic organelles, 
including early endosomes, recycling endosomes, late endosomes, and lysosomes (103). 
These organelles have membranes of different lipid, carbohydrate, and protein 
composition, and their lumen is acidified to different extents (103). I propose however 
that the results with RBCs might provide valuable insights into how E5-TAT might 
behave inside endocytic organelles.  
       Endocytic organelles have a pH ranging from approximately 6.5 for early 
endosomes to 5.5 in late endosomes and 4.5 for lysosomes (104-106). The high pK50 
observed for E5-TAT would suggest that an increase in the lytic activity of the peptide 
might occur early in the endocytic pathway. E5-TAT might rapidly bind to the 
membrane of endosomes as the vacuolar ATPase acidifies the lumen of endocytic 
organelles and form aqueous pores from which internalized macromolecules could 
escape (106). In contrast, E3-TAT, with its lower pK50, would be activated later in the 
endocytic pathway. The data however suggest that parameters other than pH will 
influence the activity of the peptides, including the presence of heparan sulfate (HS) 
proteoglycans and the lipid composition of the membrane. 
101 
 
       It is now well established that TAT binds to heparan sulfate proteoglycans (HSPGs) 
on the cell surface and that internalization of TAT is typically reduced in 
glycosaminoglycan-deficient cell lines (47,81,107,108). Soluble acidic polysaccharides 
like heparin can also compete with HSPGs for TAT binding and inhibit the translocation 
of the peptide into cells (72-74). The importance of HSPGs for TAT mediated 
translocation remains however unclear as TAT might be internalized inside cells by 
multiple nonexclusive mechanisms that may or may not involve HSPGs (109-111). 
While association of TAT to HSPGs might contribute to an increase in peptide uptake, it 
is also possible that HSPGs may sequester TAT away from the lipid bilayer and reduce 
its ability to translocate across the plasma membrane (41,112,113). It is also known that 
TAT induces the internalization of cell-surface HSPGs (114). TAT and HSPGs might 
therefore associate within endocytic compartments, and it is possible that this association 
inhibits TAT-mediated endosomal release (17,112). In addition, HS proteoglycans are 
degraded within the endocytic pathway by sequential endoglycolysis and proteolysis 
(115-118). The polysaccharide chains appear to be degraded in a stepwise manner with a 
progressive reduction in the size of the degradation fragments that correlates with the 
maturation of the endocytic compartments from early endosomes to lysosomes. Release 
of HS chains From the HSPG protein moiety and partial cleavage of the soluble HS 
chains are initiated early on in the endocytic pathway. Degradation of HS fragments one-
half to one-fourth the size of the original HS chain does not appear however to be 
completed until accumulation into lysosomes occurs. It is therefore possible that HS 
degradation does not precede TAT degradation and that soluble HS degradation 
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fragments inhibit the binding of TAT to lipid bilayers throughout the endocytic pathway. 
I am therefore interested in testing whether similar effects would be observed for E5-
TAT. In particular, binding of TAT to soluble HS might prevent E5 from binding to the 
phospholipid bilayer. On the other hand, the affinity of E5 for the lipid bilayer might 
promote the binding of E5-TAT to the bilayer regardless of whether TAT is bound to HS 
or not. To test the effect that TAT binding to HS might have on E5-TAT activity, the 
soluble HS analogue heparin was used. RBCs were again used as a model because the 
surface of RBCs has been shown to contain very low levels of HS proteoglycans 
(89,119). RBCs might therefore be comparable to the membrane of endocytic organelles 
once cleavage of the HS chains from the HSPGs has taken place. In the experiments, the 
presence of heparin had a dramatic inhibitory effect on the hemolytic activity of E5-TAT 
but not of E5. The binding of Fl-E5-TAT to RBCs was also much reduced when heparin 
was present in solution. Together, these results suggest that binding of TAT to heparin 
sequesters the E5 moiety away from the membrane of RBCs. By analogy, TAT binding 
to HS or HS fragments might inhibit the activity of E5-TAT inside endocytic organelles. 
This effect could offset the gain in lytic activity observed in Fig. 4-1A when TAT is 
conjugated to E5.  
      Molecular dynamics simulations suggest that anionic groups present in the inner 
leaflet of a biological membrane attract TAT present on the outer leaflet of the 
corresponding bilayer (120). TAT and clustered PS on either side of a bilayer have also 
been proposed to generate a local capacitor that can induce the electroporation of the 
membrane (121). It is therefore possible that TAT contributes to the lytic activity of E5-
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TAT by acting directly on lipid bilayers according to these proposed mechanisms. In 
addition, the PS asymmetry present at the plasma membrane of mammalian cells is also 
thought to be conserved at the membranes of endocytic organelles (122). In analogy to 
the binding observed between E5-TAT and ghosts, my data would then suggest that E5-
TAT could bind to exposed PS after endosomal lysis occurs. A molecular cargo attached 
to E5-TAT would then remain bound to permeabilized endosomes rather than diffuse 
freely into the cell. This is consistent with results in section 3 describing how the 
fluorescent protein HA2-TAT-mCherry, while being able to cause the release of a 
soluble dextran from endosomes into the cytosol of a cell, remains associated with 
endocytic organelles. Finally, the composition of the endocytic organelles is also known 
to change during the transition from early to late endosomes. In particular, late 
endosomes are enriched in the anionic lipid lysobisphosphatidic acid (LBPA) (123). It is 
therefore possible that, after trafficking within the endocytic pathway, E5-TAT might 
encounter a membrane leaflet more negatively charged in a late endosome than in the 
early endosome. Binding of the TAT moiety to LBPA could bring the E5 to the lipid 
bilayer. This in turn could contribute to an increase in membrane disruption by E5 in a 
pH-independent manner. 
      In conclusion, the results with RBCs provide valuable insights into the behavior of 
HA2-TAT peptides within endocytic organelles. From the point of view of the design of 
delivery agents, HA2 is employed as a pH-dependent switch that can disrupt endosomal 
membranes upon acidification. TAT, on the other hand, is added to the sequence to 
transport the HA2 moiety into the cell. The results however highlight how the lytic 
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activity of HA2 is profoundly affected by this addition. For E5-TAT, TAT affects the 
hemolytic activity, the solubility, and the binding properties of the peptide. The shifted 
pH response of E5-TAT in particular seems perfectly suited for delivery applications. 
However, TAT might also contribute to an inhibitory effect by potentially binding to HS 
and sequestering the peptide away from lipid bilayers. Together, these results provide 
the basis for the rational design of delivery agents with improved properties. 
4.4 Materials & Methods 
4.4.1 Peptide synthesis and purification
       E3-TAT, E5-TAT, Fl-E5-TAT and E5-TAT-Fl were purchased as crude cleavage 
products from RayBiotech (Norcross, GA). Peptide sequences are described in Table 4-1. 
TAT was synthesized in-house on the Rink amide resin by SPPS using standard Fmoc 
protocols. Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, 
Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, and Boc-Cys(StBu) were used to 
assemble the peptides and were purchased from Novabiochem (San Diego, CA). 
Reactions were carried out in SPPS vessels at room temperature using a stream of dry N2 
to provide agitation. Fmoc deprotection was performed by addition of piperidine in DMF 
(20%, 5 mL) to the Fmoc-peptide resin (0.72 mmol). Deprotection was carried out for 
13 min and 110 min. Coupling reactions were carried out for 2 h with a mixture of 
Fmoc-amino acid (2.88 mmol), HBTU (1.06 g, 2.80 mmol), and DIEA (1.25 mL, 7.2 
mmol) in DMF. Upon completion of the reaction, the resin was washed with DMF. The 
peptides were analyzed and purified by reverse phase HPLC. HPLC analysis was 
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performed on a Hewlett-Packard 1200 series instrument and a Vydac C18 column (5 
micron, 4 x 150 mm). Flow rate was 1 mL/min and detection was at 214 nm. Semi-
preparative HPLC was performed on a Vydac C18 10  250 mm column. Flow rate was 
4 mL/min and detection was at 214 nm. All runs used linear gradients of 0.1% aqueous 
TFA (solvent A) and 90% acetonitrile, 10% water and 0.1% TFA (solvent B). All 
purified and lyophilized peptides were dissolved to 1 mM in DMSO and diluted with 
PBS to desired concentrations in further experiments. The correct identity of the peptides 
was confirmed by MALDI-TOF mass spectrometry (AXIMA-CFR, Shimazu, Kyoto). 
TAT expected mass: 1395.7 Da, observed mass: 1395.5 Da. E3-TAT expected mass: 
3834.4 Da, observed mass: 3835.7 Da. E5-TAT expected mass: 3978.5 Da, observed 
mass: 3978.8 Da. Fl-E5-TAT expected mass: 4609.3 Da, observed mass: 4605.8 Da. E5-
TAT-Fl expected mass: 4495.3 Da, observed mass: 4501.5 Da. To obtain the E3 or E5, 
E3-TAT and E5-TAT were digested with trypsin at a peptide to enzyme ratio of 1:25 for 
5h at 37C. This procedure yielded E3 or E5 with a C-terminal arginine residue and with 
a yield of 97% (The TAT sequence is digested and the sequence of the product is 
described in Table 4-1), as demonstrated by HPLC and mass spectrometry. E3 
(GLFGAIAGFIENGWEGLIEGWYGGR) expected mass: 2667.3 Da, observed mass: 
2659.2 Da. E5 (GLFEA IAEFI ENGWE GLIEG WYGGR) expected mass: 2813.3 Da, 
observed mass: 2809.9 Da.
4.4.2 Hemolysis assays 
      A membrane lysis assay was performed with human erythrocytes purchased from the 
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Gulf blood bank (Galveston, TX). Erythrocytes were centrifuged for 5 min at 1500g; 
following 20 ml of erythrocyte pellet was resuspended with an equal volume of PBS. 
This was repeated three times to remove plasma and buffy coat. The erythrocytes (50% 
volume in PBS) were diluted 20 fold in PBS of different pH values (adjusted with HCl 
or NaOH, 4.5<pH<7.5). All peptides were diluted with PBS to desired concentrations 
and added to a 96-well plate. One hundred microliters of the 2.5% RBC suspension was 
added into each well. One hundred microliters of hemolytic peptides diluted in PBS 
from a DMSO stock (100 M) to a 2x concentration were added to the RBCs to generate 
a 1.25% suspension of cells with peptides at the desired concentration. To test the effects 
of heparan sulfate, aliquots of heparin sodium salt (sigma) stock in PBS (100 mg/mL) 
were to obtain a final concentration of 1 to 7 mg/mL Addition of heparin was done prior 
to the addition of peptide to the RBCs suspension. The plates were incubated at 37C for 
30 min. After centrifuging the plate for 5 minutes at 1500g, the supernatants were 
transferred to a new 96-well plate. The absorbance of hemoglobin present in each well 
was measured at 450 nm using a plate reader (Bio-RAD, Ultramark Micro plate system, 
USA). One hundred percent hemolysis was obtained by incubating the RBC with 0.1% 
Triton X-100. Background hemolysis at various pH was evaluated by incubating the 
erythrocytes in the corresponding PBS solutions. The obtained data was plotted using the 
software KaleidaGraph (Synergy Software, Reading, PA). The data was fitted to an 
equation of the form %=%min+(%max-%min)*[H+]/([H+]+K50), where %max and 
%min are the maximum and minimum lysis activities observed, and K50 is the proton 
concentration at which %=(%max+%min)/2, with R2 between 0.99, 0.97, 0.98 and 0.96 
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for E3-TAT, E5-TAT, E3 and E5, respectively.  
 
4.4.3 Microscopy assays 
Hemolytic peptides were added to the 1% RBC suspension in PBS at pH of 4.5 or 7 
by dilution from their DMSO stock to the desired final concentration (final DMSO 
content was kept below 5% in all experiments). After incubation at 37°C for 20 minutes, 
the solution was diluted in PBS at pH of 4.5 or 7 to obtain a 1 % suspension. Two 
hundred microliters of these suspensions were added to the wells of an 8-well chamber 
glass slide (Nunc). Cells were placed on an inverted epifluorescence microscope (Model 
IX81, Olympus, Center Valley, PA) equipped with a heating stage maintained at 37°C. 
Cells were typically allowed to settle to the bottom of the dish for 5 minutes prior to 
imaging so as to obtain a layer of cells in the focal plane. The microscope is configured 
with a spinning disk unit to perform both confocal and wide-field fluorescence 
microscopy. Images were collected using a Rolera-MGI Plus back-illuminated EMCCD 
camera (Qimaging, Surrey, BC, Canada). Images were acquired using bright field 
imaging and two standard fluorescence filter sets: Texas Red (Ex = 56040 nm / Em= 
63075 nm), and FITC (Ex = 48235 nm / Em= 53640 nm). For time-lapse 
experiments, the hemolytic peptides, prepared as 2X solutions in PBS at pH 4.5 or 7, 
were added directly to the 1% RBC suspension already placed on the microscope. To 
wash ghosts, 200 L of 2.5% RBC suspension with the hemolytic peptides were 
centrifuged for 5 minutes at 1500g. The supernatant was removed and cells were 
resuspended in 200 L fresh PBS at a desired pH. A 20 L aliquot of the cells was 
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added to an 8-well glass slide and imaged to monitor the morphology and fluorescence 
of cells. These steps were repeated 3 to 5 times, or until spherical ghosts could not be 
recovered. An aliquot of 10kDa FITC-Dextran (Invitrogen) was added to the 
resuspendend ghosts to a final concentration of 250 M. The bright field and 
fluorescence intensities of cells and ghosts were measured using the SlideBook 4.2 
software (Olympus, Center Valley, PA). Mean intensities within cells imaged was 
measured as the total intensity of the cell divided by its area. Annexin V-FITC 
(ApoDETECT KIT, Invitrogen) was incubated with RBCs lysed with E5-TAT (1 M) at 
pH 6 according to the vendor’s recommended protocol (10 L of stock solution to 190 
L of cell suspension in PBS supplemented with 2.5 mM CaCl2).  
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5. CONCLUSION 
 
      Due to its unique pH-dependent membrane disruption property, I propose HA2 
peptide can enhance endosomal escape upon endosomal acidification during CPP-
mediated protein delivery. In section 1, the covalently linked CPP protein constructs, 
HA2-TAT-mCherry and E5-TAT-mCherry were incubated with cells to test if HA2 and 
its mutant, E5 can enhance endosomal escape and release more proteins into the cytosol. 
The results revealed that HA2 and E5 are hydrophobic and tend to associate with all the 
lipid membrane compartments inside of cells. Therefore, HA2/E5-TAT-mCherry was 
only able to release the coincubated dextran molecule to the cytosol while it could not 
itself escape. This further indicates that the covalently linked strategy for HA2/E5-TAT 
with protein cargo may not be ideal for protein delivery since this CPP tag can alter the 
protein behavior. For this reason, in section 2, the endosomal escape efficiency of 
HA2/E5-TAT on mCherry was tested by simple co-incubation. It was revealed that E5-
TAT first associates with heparan sulfate proteoglycan (HSPG) on the extracellular 
matrix, then internalizes into endosomes through macropinocytosis. Next, this tag 
disrupts the endosomal membrane during endosomal acidification, releasing mCherry 
into the cytosolic space. In summary, the results showed that the efficiency of E5-TAT-
induced endosomal escape to the cytosol is only 16%, this is still an improvement over 
the 8% efficiency of HA2-TAT. Although there is still an increase for endosomal escape 
with E5-TAT, 16 % of endosomal escape is still not ideal.  
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     To further explorer the cause for the low efficiency of escape, red blood cells (RBC) 
were used to served as the model system for endosomes. Through the hemolytic assay, 
E5-TAT showed the highest pH-dependent lytic activity and pK50 (pH value at 50% 
hemolysis) of 6.7, while HA2-TAT was at 5.7. Fl-E5-TAT also showed that pH-
dependent membrane binding is suggested to be related to the hemolytic event. 
Furthermore, the peptide disrupted RBCs by forming a certain number of pores to 
release the cytosolic content into the medium. Most importantly, HSPG fragments 
showed a significant affinity for E5-TAT so that the peptide-induced hemolytic activity 
was inhibited. This observation may provide a fundamental understanding for why the 
efficiency of endosomal escape is still low. Overall, through a combination of assays 
including microscopic and biochemical with mammalian cells and RBCs, the mechanism 
of protein delivery and biological application of E5-TAT has been comprehensively 
studied. The collective results may provide the basis for the molecular design of future 
delivery agents. 
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